Document:

Exhibit 10.48

Exhibit 10.48

EXECUTION COPY

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

Amended and Restated PDT Product

Development, Manufacturing and Distribution Agreement

Novartis Pharma AG,

and

QLT Inc.

 

 

 

Amended and Restated PDT Product

Development, Manufacturing and Distribution Agreement

Table of Contents

	 	 	 	 	 
	 	 	Page:	 
	 
	 	 	 	 
	Section 1 Interpretation
	 	 	2	 
	1.1 Definitions
	 	 	2	 
	 
	 	 	 	 
	Section 2 Transition
	 	 	12	 
	2.1 General; Transition Plan
	 	 	12	 
	2.2 Novartis Obligations
	 	 	14	 
	 
	 	 	 	 
	Section 3 Product Development
	 	 	14	 
	3.1 Development Commitment
	 	 	14	 
	3.2 JCC Appointments
	 	 	14	 
	3.3 Preparation of (Initial and Annual) Global Development Plans and
Development Program Budgets
	 	 	14	 
	3.4 Development Programs and Budgets
	 	 	15	 
	3.5 Feasibility Studies
	 	 	15	 
	3.6 Cooperation
	 	 	15	 
	3.7 Interim Development Measures
	 	 	16	 
	3.8 Development After the Transition Effective Date
	 	 	16	 
	 
	 	 	 	 
	Section 4 PDT Devices
	 	 	17	 
	4.1 PDT Device Development
	 	 	17	 
	4.2 Coordination of Marketing and Educational Programs
	 	 	17	 
	4.3 PDT Devices
	 	 	17	 
	 
	 	 	 	 
	Section 5 Joint Coordinating Committee
	 	 	18	 
	5.1 Creation of JCC
	 	 	18	 
	5.2 Powers of the JCC
	 	 	18	 
	5.3 Decisions of the JCC
	 	 	19	 
	5.4 Authorities and Rules of Procedure
	 	 	19	 
	5.5 Delegation by the JCC
	 	 	19	 
	5.6 Chair of the JCC
	 	 	20	 
	5.7 Changes in the Role of the JCC After the Transition Effective Date;
Primary Contacts
	 	 	20	 
	 
	 	 	 	 
	Section 6 Project Team
	 	 	20	 
	6.1 Creation of Project Teams
	 	 	20	 
	6.2 Proceedings of Project Teams
	 	 	20	 
	6.3 Team Leader
	 	 	20	 
	6.4 Program Coordinator
	 	 	21	 
	6.5 Functions of Project Team
	 	 	21	 
	6.6 Prohibited Actions
	 	 	21	 
	6.7 Reporting Relationship
	 	 	22	 
	6.8 Changes in Role of Project Teams After the Transition Effective Date
	 	 	22	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

i

 

	 	 	 	 	 
	 	 	Page:	 
	 
	 	 	 	 
	Section 7 Personnel
	 	 	22	 
	7.1 Allocation of Personnel
	 	 	22	 
	 
	 	 	 	 
	Section 8 License Grants
	 	 	22	 
	8.1 Licenses to QLT
	 	 	22	 
	8.2 Licenses to Novartis
	 	 	24	 
	8.3 No Implied Rights
	 	 	24	 
	 
	 	 	 	 
	Section 9 Manufacturing
	 	 	25	 
	9.1 Responsibility for Product Manufacturing
	 	 	25	 
	9.2 Subcontractors
	 	 	25	 
	9.3 Production Efforts
	 	 	25	 
	9.4 Manufacture of Products
	 	 	25	 
	9.5 Management of Samples
	 	 	26	 
	9.6 Manufacture of Visudyne Product After the Transition Effective Date
	 	 	26	 
	 
	 	 	 	 
	Section 10 Marketing and Distribution
	 	 	27	 
	10.1 Distribution by Novartis
	 	 	27	 
	10.2 Market Studies
	 	 	27	 
	10.3 Product Pricing
	 	 	28	 
	10.4 Marketing
	 	 	28	 
	10.5 Product Labelling and Literature
	 	 	28	 
	10.6 Sales Reports
	 	 	28	 
	10.7 [*] Obligations
	 	 	28	 
	10.8 Option to Distribute
	 	 	28	 
	10.9 Return of Rights
	 	 	29	 
	10.10 Co-Promotion
	 	 	29	 
	10.11 Marketing and Distribution After the Transition Effective Date
	 	 	29	 
	 
	 	 	 	 
	Section 11 Regulatory Approvals
	 	 	32	 
	11.1 Regulatory Approvals
	 	 	32	 
	11.2 Regulatory Responsibility
	 	 	32	 
	11.3 Responsibility for Books and Records
	 	 	32	 
	11.4 Notice of Findings
	 	 	33	 
	11.5 Recall
	 	 	33	 
	11.6 Regulatory Approvals for Visudyne Product After the Transition Effective Date
	 	 	33	 
	 
	 	 	 	 
	Section 12 Trademarks
	 	 	34	 
	12.1 Novartis to Select Trademarks
	 	 	34	 
	12.2 Control of Trademarks
	 	 	34	 
	12.3 Review of Trademarks
	 	 	35	 
	12.4 Trademarks for Product After the Transition Effective Date
	 	 	35	 
	 
	 	 	 	 
	Section 13 Mandatory Right of First Refusal on Additional Photosensitizers
	 	 	36	 
	13.1 RFR Notice
	 	 	36	 
	13.2 Terms of RFR Notice
	 	 	36	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

ii

 

	 	 	 	 	 
	 	 	Page:	 
	 
	 	 	 	 
	13.3 Proof of Principle Required
	 	 	36	 
	13.4 Acceptance Notice
	 	 	37	 
	13.5 Agreement with Third Parties
	 	 	37	 
	13.6 Mandatory Right of First Refusal on Additional Photosensitizers After
the Transition Effective Date
	 	 	37	 
	 
	 	 	 	 
	Section 14 Right of First Option to
Commercialize Verteporfin
in Certain PDT Dermatology
Fields
	 	 	37	 
	14.1 Option Field
	 	 	37	 
	14.2 Option Notice
	 	 	37	 
	14.3 Right of First Option to Commercialize Verteporfin in Certain PDT
Dermatology Fields After the Transition Effective Date
	 	 	38	 
	 
	 	 	 	 
	Section 15 Sharing of Development Expenses
	 	 	39	 
	15.1 Parties to Fund their Share of the Cost of Development Programs
	 	 	39	 
	15.2 Funding Formula for Development Expenses
	 	 	39	 
	15.3 How Funding Obligations Met
	 	 	39	 
	15.4 Limitation on Funding
	 	 	39	 
	15.5 Inability to Meet Funding Obligations
	 	 	40	 
	15.6 Development Expenses after the Transition Effective Date
	 	 	40	 
	 
	 	 	 	 
	Section 16 Payment under the Funding Formula
	 	 	40	 
	16.1 Payments under the Funding Formula
	 	 	40	 
	 
	 	 	 	 
	Section 17 Settlement Payments
	 	 	40	 
	17.1 Payment of Settlement Payments
	 	 	40	 
	17.2 Creation of Reconciliation Statements
	 	 	41	 
	17.3 How Reconciliations Calculated
	 	 	41	 
	17.4 Who Makes and Receives Settlement Payments
	 	 	41	 
	17.5 Timing and Procedure of Settlement Payments
	 	 	41	 
	17.6 Determination of Reconciliation Thresholds
	 	 	41	 
	 
	 	 	 	 
	Section 18 Proceeds from Net Sales
	 	 	42	 
	18.1 Receipt and Distribution of Net Sales of Visudyne Products Prior to
Transition Effective Date
	 	 	42	 
	18.2 Deductions from Net Sales
	 	 	42	 
	18.3 Distribution of Remainder
	 	 	42	 
	18.4 Timing of Distributions
	 	 	42	 
	18.5 Currency and Method of Payments
	 	 	43	 
	18.6 Conversion of Currency
	 	 	43	 
	18.7 Credit to Novartis for Deficiencies
	 	 	43	 
	18.8 Proceeds From Net Sales After the Transition Effective Date
	 	 	43	 
	 
	 	 	 	 
	Section 19 Calculation of Net Proceeds
	 	 	43	 
	19.1 Proceeds Sharing
	 	 	43	 
	19.2 Modification to Division of Proceeds
	 	 	44	 
	19.3 Determination of Division of Proceeds
	 	 	44	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

iii

 

	 	 	 	 	 
	 	 	Page:	 
	 
	 	 	 	 
	19.4 Disputes as to Proceeds
	 	 	44	 
	19.5 Calculation of Net Proceeds During the Pre-Transition Period and After
the Transition Effective Date
	 	 	44	 
	 
	 	 	 	 
	Section 20 Royalty Payments after Transition Effective Date for Visudyne Products
	 	 	45	 
	20.1 Royalties
	 	 	45	 
	20.2 Royalty Reports and Royalty Payment
	 	 	45	 
	20.3 Third Party Royalties after Transition Effective Date for Visudyne Products
	 	 	46	 
	20.4 Financial Audit Rights, Reconciliation Payments; Confidentiality
	 	 	47	 
	 
	 	 	 	 
	Section 21 Relationship of the Parties and Accounting
	 	 	47	 
	21.1 Alliance Relationship
	 	 	47	 
	21.2 Authorized Expenditures
	 	 	47	 
	21.3 Accounting
	 	 	48	 
	21.4 Financial Reports
	 	 	48	 
	21.5 Books of Account and Records
	 	 	48	 
	21.6 The Parties Relationship and Accounting After the Transition Effective Date
	 	 	48	 
	 
	 	 	 	 
	Section 22 Representations and Warranties
	 	 	49	 
	22.1 Representations of Each Party
	 	 	49	 
	22.2 Title to Products
	 	 	49	 
	22.3 Representations and Warranties of Novartis
	 	 	49	 
	22.4 Representations and Warranties of QLT
	 	 	49	 
	 
	 	 	 	 
	Section 23 Limitations On Liability And Indemnity
	 	 	50	 
	23.1 SPECIFIC EXCLUSION OF OTHER WARRANTIES
	 	 	50	 
	23.2 LIMITED DAMAGES
	 	 	50	 
	23.3 MONETARY LIMIT
	 	 	50	 
	23.4 INDEMNITY ONLY REMEDY FOR INFRINGEMENT
	 	 	50	 
	23.5 Novartis Indemnity
	 	 	51	 
	23.6 QLT Indemnity
	 	 	51	 
	23.7 Limitation of Liability and Indemnity After the Transition Effective Date
	 	 	51	 
	23.8 Limitation on Indemnities
	 	 	52	 
	 
	 	 	 	 
	Section 24 Proprietary Information
	 	 	53	 
	24.1 Obligation of Confidentiality
	 	 	53	 
	24.2 Identification of Proprietary Information
	 	 	53	 
	24.3 Property in Proprietary Information
	 	 	53	 
	24.4 Acknowledgement of Confidentiality
	 	 	53	 
	24.5 Duration of Obligation
	 	 	54	 
	24.6 Exclusions from Proprietary Information
	 	 	54	 
	24.7 Disclosure to Consultants
	 	 	54	 
	24.8 Disclosure to Employees
	 	 	55	 
	 
	 	 	 	 
	Section 25 Proprietary Rights
	 	 	55	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

iv

 

	 	 	 	 	 
	 	 	Page:	 
	 
	 	 	 	 
	25.1 Patent Listing
	 	 	55	 
	25.2 Update of Listing
	 	 	55	 
	25.3 Further Information Regarding Patents
	 	 	55	 
	25.4 Ownership of Proprietary Rights
	 	 	55	 
	25.5 Ownership of Work Product in General
	 	 	55	 
	25.6 Registrations
	 	 	56	 
	25.7 Prosecution of Patents
	 	 	57	 
	25.8 Notice Requirement
	 	 	57	 
	25.9 Mandatory License
	 	 	57	 
	25.10 Patent Prosecution After the Transition Effective Date
	 	 	57	 
	 
	 	 	 	 
	Section 26 Release — Potential Disputes
	 	 	58	 
	26.1 Mutual Release
	 	 	58	 
	26.2 MEEI Litigation
	 	 	58	 
	26.3 MGH Litigation
	 	 	59	 
	 
	 	 	 	 
	Section 27 Term and Termination
	 	 	60	 
	27.1 Term
	 	 	60	 
	27.2 Expiration of Term
	 	 	60	 
	27.3 Early Termination
	 	 	61	 
	27.4 General Effect of Early Termination
	 	 	61	 
	27.5 Effect of Termination Due to An Event of Default
	 	 	62	 
	27.6 Effect of Termination for Convenience
	 	 	63	 
	27.7 Rights to Visudyne Product in the Other’s Territory After Certain Terminations
	 	 	63	 
	 
	 	 	 	 
	Section 28 Rights in Bankruptcy
	 	 	63	 
	 
	 	 	 	 
	Section 29 General
	 	 	64	 
	29.1 Amendment
	 	 	64	 
	29.2 Arbitration
	 	 	64	 
	29.3 Assignment
	 	 	65	 
	29.4 Counterparts; Facsimile
	 	 	66	 
	29.5 Drafting
	 	 	66	 
	29.6 Entire Agreement
	 	 	66	 
	29.7 Enurement
	 	 	67	 
	29.8 Force Majeure
	 	 	67	 
	29.9 Headings
	 	 	67	 
	29.10 Law; Courts
	 	 	67	 
	29.11 Non-Competition
	 	 	68	 
	29.12 Notice
	 	 	68	 
	29.13 Publicity
	 	 	69	 
	29.14 Publications
	 	 	69	 
	29.15 Severability
	 	 	69	 
	29.16 Sharing of Information
	 	 	70	 
	29.17 Survival
	 	 	70	 
	29.18 Waiver
	 	 	70	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

v

 

Table 1: List of Schedules

	 	 	 	 	 	 	 
	Section:	 	 	 	Page:	 
	 	 	 
	 	 	 	 
	1.1.29:	 	Joint Patents
	 	 	73	 
	1.1.42:	 	Novartis [*] Patents
	 	 	74	 
	1.1.44:	 	Novartis Patents
	 	 	75	 
	1.1.64:	 	QLT Patents
	 	 	76	 
	1.1.81:	 	Visudyne Trademark
	 	 	77	 
	5.4:	 	JCC Authorities and Rules of Procedure
	 	 	78	 
	10.1:	 	Novartis Distributorship Countries
	 	 	81	 
	11.1.1:	 	Novartis Basic International Registration Documentation
	 	 	84	 
	28.11:	 	Novartis Affiliates
	 	 	85	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

vi

 

Amended and Restated PDT Product

Development, Manufacturing and Distribution Agreement

This Amended and Restated PDT Product Development, Manufacturing and Distribution Agreement (the
“Agreement”) is made effective as of October 16, 2009 (the “Restatement Date”), by and between
Novartis Pharma AG, a Swiss corporation having a principal place of business at Lichtstrasse 35,
4056 Basel, Switzerland (“Novartis”) and QLT Inc., a British Columbia company having a principal
place of business at 887 Great Northern Way, Suite 101, Vancouver, British Columbia, Canada, V5T
4T5 (“QLT”).

WHEREAS, Novartis Ophthalmics AG (formerly Ciba Vision AG) and Novartis Pharma AG merged effective
July 1, 2003 to become Novartis Pharma AG;

WHEREAS, Novartis and QLT, Inc., formerly known as Quadra Logic Technologies Inc., entered into a
PDT Product Development, Manufacturing and Distribution Agreement made effective July 1, 1994 (the
“Co-Development Agreement”), under which Novartis and QLT agreed to cooperate in the development,
manufacturing and distribution of photosensitizers in photodynamic therapy for the treatment,
diagnosis and prevention of ophthalmologic conditions;

WHEREAS, Novartis and QLT entered into an Amending Agreement made effective July 23, 2001 (the
“First Amendment”) under which QLT and Novartis agreed to co-develop Verteporfin (as defined
herein) for use in photodynamic therapy in connection with the treatment, diagnosis or prevention
of dermatological tumours, and other pathological conditions of the skin in which the primary cause
is attributable to vascular abnormalities but excluding psoriasis, and excluding the use of
Verteporfin in PDV (as defined herein), on the terms and conditions set out therein;

WHEREAS, QLT and Novartis entered into an Amending Agreement made effective July 22, 2003 (the
“Second Amendment”) to terminate the First Amendment and return to QLT all rights granted
thereunder;

WHEREAS, pursuant to the Second Amendment QLT granted to Novartis a right of first option to
negotiate to participate in the commercialization of Verteporfin in PDT in dermatological
conditions other than dermatological tumors;

WHEREAS, neither party has at any time given notice of first refusal in respect of any Additional
Photosensitizers in accordance with Section 13.1 of the Agreement and the scope of collaboration
as at the Restatement Date is limited to the Visudyne Product; and

WHEREAS, QLT and Novartis have, as of the Restatement Date, agreed to modify certain terms of the
Agreement, and to license to QLT all rights to continue to develop, and commercialize Verteporfin
in the United States.

NOW THEREFORE, in consideration of the premises and the mutual covenants and agreements contained
in this Agreement, the parties hereto agree as follows:

 

1

 

Section 1 Interpretation

	1.1	 	Definitions

For the purposes of this Agreement, the following words shall have the following meanings:

1.1.1 “Acceptable Levels of Efficacy or Safety” means, in respect of any Product, the minimum
requirements in a clinical study for the efficacy or safety performance of the Product as set out
in the clinical protocol for such study, or, to the extent not specified therein, as may be
determined by the JCC prior to the commencement of the clinical study;

1.1.2 “Acceptance Notice” has the meaning set out in Section 13.4;

1.1.3 “Additional Photosensitizer” means any Photosensitizer in the Field other than BPD or
ZnPc developed by, licensed to, acquired by or otherwise commercially accessible to either party as
at the Effective Date or during the term of this Agreement until the Restatement Date and in
respect of which the other shall have exercised its right of first refusal in accordance with
Section 13;

1.1.4 “Affiliate” means, with respect to each party, any legal entity that directly or
indirectly controls, is controlled by, or is under common control with, such party, but only for so
long as such control shall continue. One entity shall be deemed to control another entity if such
entity has the power to direct or cause the direction of the management or policies of the other
entity;

1.1.5 “Alliance” means the association formed by QLT and Novartis for the purposes set out in
this Agreement with respect to Products prior to the Transition Effective Date;

1.1.6
“Applicable Law” means all laws, statutes, ordinances, codes, rules, and regulations
that have been enacted by a supranational, national, or regional, state, provincial or other local
government, court, governmental agency, authority, board, bureau, instrumentality, regulatory
authority, or other government entity, including without limitation good clinical practices
(“GCP”), good laboratory practices (“GLP”), and current good manufacturing practices (“GMP”), and
which are in force as of the Effective Date or come into force during the term of this Agreement,
in each case to the extent that the same are applicable to the performance by the parties of their
respective obligations under this Agreement;

1.1.7 “Approved Product” means in respect of any given country any Product for which Marketing
Approval in respect of a specific ophthalmologic indication has been obtained in such country;

1.1.8 “Assets” means all the real or personal property, assets and rights used in connection
with or by the Alliance from time to time and beneficially owned equally by the parties, including
capital assets;

1.1.9 “BIRD” has the meaning set out in Section 11.1.1;

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

2

 

1.1.10 “BPD” means any pharmaceutical product which contains Benzoporphyrin derivative as an
active ingredient for use in PDT and, for greater certainty, includes Verteporfin;

1.1.11 “Business Day” means a day that is not a Saturday or Sunday or a national holiday in
either Canada or Switzerland;

1.1.12 “Calendar Quarter” means the respective periods of three (3) consecutive calendar
months ending on March 31, June 30, September 30, and December 31; provided, however, that (a) the
first Calendar Quarter of the term of this Agreement after the Restatement Date will extend from
the Restatement Date to the end of the first complete Calendar Quarter thereafter; and (b) the last
Calendar Quarter will end upon the expiration or termination of this Agreement;

1.1.13
“Cease to Commercialize” or
“Cessation of Commercialization” means, as to a party in
a given country within its territory under this Agreement, that such party has not sold any Product
in such country for a period [*], except if (i) the parties agree otherwise or (ii) [*] or (iii)
such lack of sales is attributable to an event of force majeure (or in the case of Novartis, the
failure by QLT to supply Product);

1.1.14 “[*]” has the meaning set out in [*];

1.1.15
“Control”, “Controls” or
“Controlled” means the legal authority or right of a party to
grant a license or sublicense as provided for herein without violating the terms of any agreement
or other arrangement with any Third Party or misappropriating the proprietary or trade secret
information of a Third Party;

1.1.16 “Denali Study” has the meaning set out in Section 3.8.2;

1.1.17 “Development” means with respect to any Product prior to the Transition Effective Date
all work carried out in accordance with a Development Program, including non-clinical and clinical
studies, required to obtain health regulatory approvals in all countries in the Territory
determined to be necessary or desirable by the JCC and all subsequent work prior to the Transition
Effective Date required to maintain or defend such approval, and premarketing activities conducted
prior to such approval;

1.1.18 “Development Expenses” means those costs and expenses, comprised of Labour and Third
Party Costs, incurred subsequent to the Effective Date and prior to the Transition Effective Date
in accordance with Section 15 that have been approved by the JCC from time to time, and, unless
otherwise determined by the JCC, shall include the following:

1. costs of Labour employed on Development Programs including regulatory
work and preparation of submissions;

2. cost of manufacture of supplies of drugs for non-clinical and clinical
studies;

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

3

 

3. costs of acquiring devices for clinical and non-clinical use with
Products in Development Programs;

4. costs of conducting feasibility studies to determine the appropriateness
of commencing a Development Program for a specific indication;

5. costs incurred by either party or the Alliance in acquiring such
improvements, facilities, equipment, materials or supplies as may be
necessary for the establishment and conduct of Development;

6. costs of market research for the selection of indications and other
premarketing activities for Products;

7. costs of developing and evaluating alternative formulations for Products;

8. costs of preparing the Global Development Plan and any Development
Programs; and

9. any costs or expenses as incurred and which are incidental to Development
which are designated as Development Expenses by the JCC;

but does not include:

10. costs of participation by QLT and Novartis in the JCC, or compensation
for personnel, travel costs and other out-of-pocket costs in respect of the
JCC and its operation;

11. depreciation on any Assets; and

12. the proportionate costs incurred by a party with respect to its
Photosensitizers for use outside the Field;

1.1.19 “Development Program” means a program developed by a Project Team and approved by the
JCC for the Development of a Product through to commercialization and, where the JCC deems
appropriate, in respect of specific ophthalmologic indications within the Field and shall include a
budget, tasks and timelines. A Development Program can include Development of an Approved Product
prior to the Transition Effective Date in a country for any indication other than indications, if
any, for which Marketing Approval has been obtained in such country;

1.1.20 “Drug Owner” means, in respect of BPD, QLT, in respect of ZnPc, Novartis, in respect of
any Additional Photosensitizer, the party giving notice of a right of first refusal in accordance
with Section 13.1;

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

4

 

1.1.21 “Effective Date” means the effective date of the Co-Development Agreement, which is
July 1, 1994;

1.1.22 “Expiration Date” has the meaning set out in Section 27.2;

1.1.23 “Event of Default” has the meaning set out in Section 27.3.2;

1.1.24 “Field” means any usage of PDT for the treatment, diagnosis or prevention of
ophthalmologic conditions, including but not limited to, age-related macular degeneration (“AMD”),
diabetic retinopathy, corneal neovascularization, ocular tumours and epithelial overgrowth
following cataract surgery (secondary cataracts);

1.1.25 “Funding Formula” has the meaning set out in Section 15.2;

1.1.26 “Global Development Plan” means the plan approved by the JCC for all Development, which
shall include each Development Program approved by the JCC and estimates of all Development
Expenses of all such activities of the parties through to commercialization contemplated by this
Agreement and shall include all appropriate measures to protect against potential cross-sales
identified by the JCC as a condition of such Development prior to the Restatement Date;

1.1.27 “Initial Global Development Plan” means the Global Development Plan to be approved by
the JCC on or before December 31, 1995 as provided in Section 3.3;

1.1.28 “JCC” or “Joint Coordinating Committee” means the committee consisting of three senior
personnel from each of QLT and Novartis established pursuant to Section 5;

1.1.29 “Joint Patents” means all Patents having claims reading on Products or portions
thereof, or methods of manufacture or use thereof, and claiming an invention conceived jointly by
employees, agents or licensors of both QLT and Novartis during the term of this Agreement
applicable to both BPD and ZnPc, including any continuations, continuations in part, divisions,
reissues and reexaminations thereof (including without limitation those listed on Schedule 1.1.29);

1.1.30
“Know-How” means (a) ideas, discoveries, inventions, improvements, technology or trade
secrets, (b) pharmaceutical, chemical and biological materials, products, components or
compositions, (c) tests, assays, techniques, regulatory requirements and strategies, data
(including non-clinical and clinical data), methods, procedures, formulas or processes, (d)
technical and non-technical data and other information relating to any of the foregoing, (e)
drawings, plans, designs, diagrams, sketches, specifications or other documents containing or
relating to such information or materials, and (f) business processes, price data and information,
marketing data and information, sales data and information, marketing plans and market research;

1.1.31 “Labour” means salaries, benefits and other reasonable costs and expenses of personnel
of either party charged on the basis of a standard fixed amount per person month for

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

5

 

all personnel, with such rate to be as established by the JCC, and labour which is designated
as Labour by the JCC;

1.1.32 “Marketing Approval” means in respect of any given country the receipt of all final
regulatory or pricing approvals that are reasonably required to commercially market and sell a
Product in respect of a specific ophthalmologic indication in such country;

1.1.33 “Manufacturing Expenses” means those costs and expenses that have been approved by the
JCC from time to time in connection with the manufacture of Products prior to the Transition
Effective Date and, unless otherwise determined by the JCC, shall include the following:

1. direct out-of-pocket costs, including applicable non-refundable duties
and taxes, for raw materials, packaging and other supplies consumed or used
in the manufacturing process;

2. salaries and benefits of personnel employed directly for the manufacture
of a Product, including quality assurance procedures;

3. a reasonable allocation for overhead computed as a mutually agreed to
percentage of the sum of the amounts computed pursuant to Sections 1.1.33.1
and 1.1.33.2; and

4. interest computed on inventory at a nominal interest rate to be mutually
agreed upon;

but shall not include the following:

5. any other corporate allocations or other charges not directly related to
the manufacture of a Product; and

6. amortization charges for any development expenditures;

1.1.34 “Marketing and Distribution Expenses” means those costs and expenses that have been
approved by the JCC from time to time in connection with the marketing and distribution of Products
prior to the Transition Effective Date and, unless otherwise determined by the JCC, shall include
the following:

1. product-specific marketing expenses incurred for physician training,
direct advertising, films, samples, exhibits, clinical conference aids, peer
promotion activities, marketing research and other direct out-of-pocket
costs normally included as marketing expenses by Novartis’ standard
accounting procedures;

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

6

 

2. direct costs, including salaries, employment and transportation benefits
for Novartis’ field sales force properly allocated to the sale of Products
in accordance with Novartis’ standard accounting procedures;

3. a reasonable allocation of overhead costs computed as a mutually agreed
to percentage of such costs;

4. direct out-of-pocket costs for distribution, transport, and storage of
Product;

5. costs incurred for any post-market surveillance studies approved by the
JCC for any Product;

6. inventory spoilage, receivable write-offs and reasonable allowances for
bad debts;

7. interest computed on inventory and receivables at a nominal interest rate
to be mutually agreed upon; and

8. any other costs or expenses incurred which are incidental to the
marketing or distribution of any Product which are designated as Marketing
and Distribution Expenses by the JCC;

but shall not include the following:

9. costs relating to the registration or maintenance of any trademarks used
with any Product;

10. any other corporate allocations or other charges not directly related to
the marketing and distribution of a Product; and

11. amortization charges for any deferred expenditures;

1.1.35 “MEEI” has the meaning set out in Section 26.2.1;

1.1.36 “MGH” means General Hospital Corporation, doing business as Massachusetts General
Hospital;

1.1.37 “MGH Agreement” means the License Agreement entered into by and between QLT and MGH,
effective as of December 8, 1998;

1.1.38 “MSA” has the meaning set out in Section 9.6.2;

1.1.39 “Net Proceeds” has the meaning set out in Section 19.1;

1.1.40 “Net Sales” in any Calendar Quarter means (A) in respect of sales of Products prior to
the Transition Effective Date all revenue from the sale or exploitation in any manner of

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

7

 

Products in such quarter by Novartis or its Affiliates or sublicensees to Third Parties, to
the extent actually taken, granted, or incurred by Novartis in accordance with IAS18 criteria,
less:

1. trade and/or quantity discounts actually allowed;

2. sales, value added or other excise taxes paid on the sale of the Products
that are non-refundable;

3. amounts repaid or credited by reason of purchase chargebacks, rebates,
rejections or returns;

4. charges for freight, handling and transportation separately billed; and

(B), solely, in respect of sales of Visudyne Product upon and after the Transition Effective Date,
shall mean the net sales on behalf of Novartis and any of its Affiliates or sublicensees for the
Visudyne Product sold to Third Parties other than sublicensees in bona fide, arms-length
transactions, as determined [*] in accordance with IFRS (International Financial Reporting
Standards) as consistently applied at Novartis, including [*] and any amounts credited for
uncollectible amounts on previously sold products.

1. In the case of any sale or other disposal of a Visudyne Product between
or among Novartis and its Affiliates or sublicensees, for resale, Net Sales
shall be calculated only on the value charged or invoiced on the first
arm’s-length sale thereafter to a Third Party;

2. In the case if any sale which is not invoiced or is delivered before the
invoice, Net Sales shall be calculated at the time all the revenue
recognition conditions under IFRS are met;

3. In the case of any sale or other disposal for value, such as barter or
counter-trade, of any Visudyne Product, or part thereof, other than in an
arm’s length transaction exclusively for money, Net Sales shall be
calculated on the value of the non-cash consideration received or the fair
market price (if higher) or the Visudyne Product in the country of sale or
disposal; and

4. In the event the Visudyne Product is sold [*], the Net Sales of the
Visudyne Product, for the purposes of determining royalty payments, shall be
[*].

5. For the avoidance of doubt, sales between Novartis, its Affiliates,
sublicensees and designees shall not be considered Net Sales (unless such
entity is the end user of the Visudyne Product), which shall be calculated
on Net Sales of Novartis, its Affiliates, sublicensees and designees to
independent third party customers.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

8

 

1.1.41 “Novartis Affiliates” has the meaning set out in Section 28.11;

1.1.42 “Novartis [*] Patents” means [*], and any Patents which claim priority thereto
(including without limitation those listed on Schedule 1.1.42);

1.1.43 “Novartis Know-How” means Know-How owned or Controlled by Novartis or any of its
Affiliates as of the Restatement Date relating to the Product and thereafter during the term of
this Agreement relating to the Visudyne Product that is necessary or useful for the research,
development, manufacture or use or sale of the Visudyne Product in the QLT Territory. Novartis
Know-How shall exclude Novartis Patents;

1.1.44 “Novartis Patents” means the Patents listed in Schedule 1.1.44, and any other Patents
owned or Controlled by Novartis or any of its Affiliates as of the Restatement Date or thereafter
during the Term of this Agreement having claims covering the Visudyne Product, its use,
composition, formulation, preparation or manufacture or having claims that are reasonably necessary
or useful for the research, development, manufacture, use or commercialization of the Visudyne
Product, wherein Novartis Patents shall in all cases exclude the Novartis [*] Patents;

1.1.45 “Novartis Releasees” has the meaning set out in Section 26.2.1;

1.1.46 “Novartis Technology” means the Novartis Know-How and the Novartis Patents;

1.1.47 “Novartis Territory” means (i) before the Transition Effective Date, the world and (ii)
after the Transition Effective Date, the world, excluding the QLT Territory;

1.1.48 “Option Field” has the meaning set out in Section 14.1;

1.1.49 “Option Notice” has the meaning set out in Section 14.2.1;

1.1.50 “Optional Research and Development” has the meaning set out in Section 15.5;

1.1.51 “Patents” means (a) letters patent (or other equivalent legal instrument), including
without limitation utility and design patents, and including without limitation any extension,
substitution, registration, confirmation, reissue, re-examination or renewal thereof, (b) an
application for letters patent, including without limitation a reissue application, a
re-examination application, a continuation application, a continued prosecution application, a
continuation-in-part application, a divisional application or any equivalent thereof that is
pending at any time during the term of this Agreement before a government patent agency, and (c)
all foreign or international equivalents of any of the foregoing in any country;

1.1.52 “PDV” means the use of a photosensitizer in the photodynamic treatment of one lesion in
conjunction with the administration of an immunoadjuvent to stimulate an immune response to effect
treatment of distant lesions in humans (thereby creating an immune response to cancer cells);

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

9

 

1.1.53 “PDT” means the field of photodynamic therapy, that is, the emerging medical field that
uses photosensitive compounds and light in the diagnosis, treatment or prevention of human
diseases;

1.1.54 “Photosensitizer” means any photosensitive compounds for use in PDT;

1.1.55 “Pre-Transition Period” means the time period commencing upon the Restatement Date and
ending upon the day immediately prior to the Transition Effective Date during which (i) Novartis
will (insofar as it is able) transfer to QLT certain agreements to which it or its Affiliates are a
party that are applicable to the manufacture, supply and commercialization of the Visudyne Product,
and (ii) the parties will perform such further acts as may be necessary to enable QLT to
commercialize the Visudyne Product in the QLT Territory upon and after the Transition Effective
Date, all as set forth in Section 2;

1.1.56 “Prime Rate” means the rate per year from time to time announced by the Union Bank of
Switzerland as the reference rate to determine interest payable on commercial loans to its most
creditworthy customers;

1.1.57 “Product” means (i) prior to the Transition Effective Date:

1. BPD;

2. ZnPc; and/or

3. any Additional Photosensitizer;

for use in the Field and (ii) after the Transition Effective Date the Visudyne
Product in its form as of the Transition Effective Date for use in the Field;

1.1.58 “Product under Development” means a given Product within the Field that is the subject
of a Development Program prior to the Transition Effective Date but excludes in reference to any
country any indications for which Marketing Approval has been obtained in any such country;

1.1.59 “Program Coordinator” means, in respect of any Development Program, the individual
appointed as Program Coordinator from among the Team Leaders as set out in Section 6.4;

1.1.60 “Project Team” has the meaning set out in Section 6;

1.1.61 “Proprietary Information” means, in respect of each party, any information relating to
PDT, Photosensitizers, the Products, and such party’s business or other activities that is not
generally known to the public or to other persons who are not bound by obligations of
confidentiality and:

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

10

 

1. from which such party derives economic value, actual or potential, from
not being generally known; or

2. in respect of which such party otherwise has a legitimate interest in
maintaining secrecy;

1.1.62 “QLT [*] Patents” means [*], and any Patents which claim priority thereto;

1.1.63 “QLT Know-How” means Know-How owned or Controlled by QLT or any of it’s Affiliates as
of the Restatement Date relating to the Product and thereafter during the term of this Agreement
relating to the Visudyne Product that is necessary or useful for the research, development,
manufacture or use or sale of the Visudyne Product in any country in the Novartis Territory. QLT
Know-How shall exclude QLT Patents;

1.1.64 “QLT Patents” means the Patents listed in Schedule 1.1.64, and any other Patents owned
or Controlled by QLT or any of its Affiliates as of the Restatement Date or thereafter during the
Term of this Agreement having claims covering the Visudyne Product, its use, composition,
formulation, preparation or manufacture or having claims that are reasonably necessary or useful
for the research, development, manufacture, use or commercialization of the Visudyne Product, in
all cases excluding the QLT [*] Patents;

1.1.65 “QLT Releasees” has the meaning set out in Section 26.2.2;

1.1.66 “QLT Technology” means the QLT Know-How and the QLT Patents;

1.1.67 “QLT Territory” means, upon and after the Transition Effective Date the United States
of America, its territories and possessions;

1.1.68 “Reconciliation Threshold” has the meaning set out in Section 17.6;

1.1.69 “RFR Notice” has the meaning set out in Section 13.1;

1.1.70 “Settlement Payment” means the payment of the excess of Development Expenses borne by
one party to the other pursuant to Section 17;

1.1.71 “Team Leader” means, in respect of each Project Team, a representative of a party
appointed as the Team Leader of that party as set out in Section 6.3;

1.1.72 “Third Party Costs” means those Development Expenses which are incurred by a Project
Team in accordance with the budget set in a Development Program by the purchase of goods or
services from an arm’s length third party, and is made up of all manner of Development Expenses
except Labour;

1.1.73 “Territory” means worldwide;

1.1.74 “Third Party” means any person, firm, or corporate entity other than a party hereto or
an Affiliate of a party hereto;

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

11

 

1.1.75 “Third Party Royalty” means amounts (including, but not limited to, royalties on net
sales) payable to a Third Party in connection with licenses under intellectual property rights for
the research, development, use, sale, offer for sale, importation and manufacture of the Visudyne
Product, for the avoidance of doubt any ongoing payments due to MEEI and to MGH arising from the
litigation referred to at Section 26 are not Third Party Royalties;

1.1.76 “Transition Effective Date” means January 1, 2010;

1.1.77 “UBC” means the University of British Columbia;

1.1.78 “UBC Agreement” means the Amended and Restated License Agreement entered into by and
between QLT and UBC dated January 1, 2008;

1.1.79 “Verteporfin” means benzoporphyrin derivative mono acid ring A, as more fully described
in Exhibit A;

1.1.80 “Visudyne Inventions” has the meaning set out in Section 25.5.4;

1.1.81 “Visudyne Trademark” means the trademark(s) listed on Schedule 1.1.81;

1.1.82 “Visudyne Product” means Verteporfin for use in the Field;

1.1.83 “Wet AMD” means the wet form of AMD;

1.1.84 “Work” means the activities to be carried out under this Agreement; and

1.1.85 “ZnPc” means any pharmaceutical product which contains Zinc Phythalocyanine as an
active ingredient for use in PDT.

Section 2 Transition

	2.1	 	General; Transition Plan

2.1.1 The parties have agreed, as of the Restatement Date, to restructure certain of their
rights and obligations under this Agreement with respect to the Products, in particular the
Visudyne Product. Generally, the parties intend that: (i) they shall cease any joint Development
of Products and any corresponding Development Programs with respect to any Products under this
Agreement, including but not limited to the Visudyne Product, upon and after the Transition
Effective Date; (ii) they shall cease to share Development Expenses, Manufacturing Expenses,
Marketing and Distribution Expenses, Net Proceeds and Settlement Payments in connection with
activities conducted with respect to any Product, including the Visudyne Product, upon and after
the Transition Effective Date, (iii) they shall cooperate during the Pre-Transition Period to the
extent reasonably practicable to effect a transition of all rights to commercialize the Visudyne
Product in the United States to QLT so that QLT may commence commercialization of the Visudyne
Product in the QLT Territory on the Transition Effective Date, (iv) Novartis shall bear all
expenses incurred in connection with the Visudyne Product upon and after the Transition

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

12

 

Effective Date arising from the development and commercialization thereof in the Novartis
Territory, and pay to QLT a royalty on Net Sales of Visudyne Product in the Novartis Territory upon
and after the Transition Effective Date, instead of the share of Net Proceeds of the Product being
shared with QLT as of the Restatement Date, (v) QLT shall bear all expenses incurred in connection
with the Visudyne Product upon and after the Transition Effective Date arising from the development
and commercialization thereof in the QLT Territory, on a royalty-free, fully-paid basis, (vi) QLT
shall continue to supply to Novartis Visudyne Product for the Novartis Territory pursuant to an MSA
(to be entered into as soon as reasonably practicable after the Restatement Date) specifying the
terms and conditions of such supply arrangement, including without limitation a supply price that
Novartis shall pay to QLT for the Visudyne Product and (vii) Novartis will make the final
distribution of Net Proceeds due to QLT pursuant to Section 19 in respect of the period prior to
the Transition Effective Date in accordance with the established process and timing the parties
have been using as of the Restatement Date. Accordingly, the parties have amended their rights and
obligations under this Agreement to reflect the foregoing and other rights and obligations
necessary to effect the foregoing. In general, in each section below the modified terms and
conditions applicable to the development, manufacture and commercialization of the Products after
the Transition Effective Date are set out separately following provisions addressing the parties’
rights and obligations with respect to Products prior to the Transition Effective Date.

2.1.2 Within [*] after the Restatement Date, the parties shall mutually agree on a transition
plan (the “Transition Plan”) which will specify each party’s responsibilities with respect to, and
the timing for, the transition of certain responsibilities of Novartis to QLT during the
Pre-Transition Period to effect the reallocation of rights to the Products as set forth in Section
2.1.1 and elsewhere in this Agreement. The Transition Plan will include without limitation the
following provisions, and such other provisions as may be necessary to transfer efficiently and
promptly to QLT rights and responsibilities for development, manufacture, sale, promotion and
distribution of Visudyne Product in the QLT Territory as of the Transition Effective Date: (a) the
assignment of any labeling, distribution and sales agreements in effect as of the Restatement Date
between Novartis and any Third Party that relate to the sale, promotion or distribution of the
Visudyne Product in the QLT Territory, to the extent permitted under those agreements, or if such
assignment is not permitted under the terms of such agreements, the transfer to QLT of Novartis’
rights under such agreements by another mechanism closely approximating the effect of such
assignment to the extent permitted by such agreements; (b) the provision by Novartis to QLT of a
list of all government entities required to be notified in respect to the transfer of
responsibility for the sale, promotion and distribution of the Visudyne Product from Novartis to
QLT, (c) a schedule for Novartis to make the communications to the entities included in the
foregoing list (with QLT to be copied on such communications concurrently); and (d) the amendment,
as soon as reasonably practicable after the Restatement Date, of the pharmacovigilance agreement
entered into by and between the parties effective as of January 15, 2004, as necessary to reflect
the modified rights and responsibilities of each party with respect to Visudyne Product pursuant to
this Agreement. In the event that any agreements described in subsection (a) contain limitations on
the assignment or transfer of Novartis’ rights thereunder to QLT, Novartis will inform QLT promptly
of the existence and terms of engagement with the relevant Third Party with respect to such
agreements, and the parties shall cooperate to establish

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

13

 

promptly an appropriate alternative mechanism for transferring the benefit of such agreement
to QLT efficiently and promptly for purposes of developing, manufacturing and commercializing
Visudyne Product in the QLT Territory upon and after the Transition Effective Date.

	2.2	 	Novartis Obligations

2.2.1 Novartis will cooperate with QLT in good faith to effect a smooth transition in
accordance with the Transition Plan during the Pre-Transition Period. As soon as reasonably
practicable after the Restatement Date, but in no case later than the Transition Effective Date,
Novartis will transfer to QLT copies of all available sales records and customer lists for the
Visudyne Product in the QLT Territory acquired or maintained by Novartis, including identification
of customers and/or quantities of Visudyne Product sold to such customers. Upon and after the
Transition Effective Date, Novartis shall, to the extent reasonably practicable and in a timely
manner, comply with any reasonable written request from QLT for further information with regard to
such sales records and customer lists.

Section 3 Product Development

	3.1	 	Development Commitment

The parties hereby agree to jointly undertake the Development of the Products within the Field
pursuant to the terms of this Agreement. Without limiting the generality of the foregoing, QLT and
Novartis shall carry out the Development by planning, collaborating on, and performing mutually
agreed-to Development Programs for Products, and shall implement the Global Development Plan.

	3.2	 	JCC Appointments

As soon as is reasonably possible after the Effective Date, the parties shall select their
respective appointments to the JCC as provided for in Section 5.

	3.3	 	Preparation of (Initial and Annual) Global Development Plans and Development Program Budgets

On or before December 31, 1995 and by no later than seventy five (75) days before the commencement
of each calendar year thereinafter, the JCC shall consider and approve annually a Global
Development Plan, including a budget for all planned Development Expenses for all Development
Programs on a calendar year basis for each year until the expected date of commercialization. The
budget shall designate all expenditures listed in such budget as either discretionary or required
items. Each Global Development Plan shall set forth in reasonable detail, for the following
calendar year, all anticipated Development Programs and any non-routine activities which the JCC
anticipates with respect to Development.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

14

 

	3.4	 	Development Programs and Budgets

From the Effective Date, QLT and Novartis will immediately undertake the following Development
Programs:

3.4.1 the development of BPD in AMD and/or other ophthalmic indications in the Field as
decided by the JCC;

3.4.2 a feasibility study of ZnPc in AMD in the Field, and any additional work for same
approved by the JCC; and

3.4.3 any other Development approved by the JCC for an Additional Photosensitizer.

The initial draft of each Development Program and each budget in respect of same shall be prepared
by the Project Team constituted by the JCC to conduct such Development Program, and shall be
submitted to the JCC at least fifteen (15) days prior to the meeting of the JCC at which such plan
and budget is to be considered. There will be at least one Development Program, and, where
appropriate, the JCC may establish additional Development Programs for significant ophthalmologic
applications. Each Development Program shall include annual operating budgets, objectives,
schedules and milestones for Development. Wherever possible, plans for Development Programs will
include assignments of sub-projects to individuals or to corporate units or to third parties.
Examples are the preparation in whole or in part of regulatory submissions, or conduct of clinical
trials.

	3.5	 	Feasibility Studies

Before deciding to establish a Development Program, the JCC, if already constituted, may direct
that some additional discovery, research effort or evaluation is required to establish the
feasibility of a Development Program. The planning, implementation and management of these studies
may be assigned by the JCC to any Project Team which has been constituted and that the JCC
determines is appropriate, and the costs incurred in such additional discovery research efforts and
evaluation shall be considered Development Expenses under the terms of this Agreement.

	3.6	 	Cooperation

Each party shall cooperate with and assist the other to perform its Development obligations
hereunder, which cooperation and assistance shall include but not be limited to the following:

3.6.1 each party shall provide the other with all information and material in such party’s
care or control that the other reasonably requires to perform its obligations hereunder; and

3.6.2 where such party’s acceptance, verification, validation, or other review of deliverables
prepared by the other is required, such party shall promptly and diligently attend to same and
communicate its approval or comments to the other, and in any event no later than fourteen (14)
calendar days after such response is requested or received, whichever is later.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

15

 

	3.7	 	Interim Development Measures

3.7.1 Interim Development Activities. Until the Initial Global Development Plan is approved
in accordance with the terms of this Agreement, any development activities by either party will
only be considered as Development under this Agreement if the representatives of QLT and Novartis
referred to in Section 3.2 have mutually agreed in writing to consider the costs which may occur in
this period as Development Expenses.

3.7.2 Interim Development Expenses. QLT and Novartis shall share in accordance with the
Funding Formula all Development Expenses for the interim Development activities for the period from
July 1, 1994 through to the commencement of the Initial Global Development Plan, expected to be no
later than December 31, 1995.

3.7.3 Responsibilities. The parties hereto will keep each other informed at regular intervals
of the interim development activities. Each party will appoint a member of its staff to liaise
with the other party throughout this interim period. The persons appointed at the Effective Date
to carry out such function shall be Dr. Gustave Huber for Novartis and Dr. Vincent Salvatori for
QLT.

	3.8	 	Development After the Transition Effective Date

3.8.1 Upon and after the Transition Effective Date, the parties will cease to perform under
any Development Programs with regard to all Products and will not initiate any joint Development
activities for any Products. Sections 3.1 through 3.7 shall be of no further force or effect as of
the Transition Effective Date.

3.8.2 As of the Restatement Date, Novartis is currently performing a clinical trial under the
code “CBPD952A2308 (DENALI)” (the “Denali Study”). Novartis shall have the right to continue or to
terminate the Denali Study at its sole discretion. Novartis shall notify QLT about the results of
the Denali Study in writing five (5) days before scientific communication or any other publication
of the results; provided that the notice provisions contained in Section 29.14 shall not apply for
the purposes of this Section 3.8.2. During the performance of the Denali Study, Novartis shall
continue to have access to clinical sites and physicians with respect to the Visudyne Product in
the QLT Territory solely to the extent necessary to complete the Denali Study. As of the
Restatement Date, Novartis is also supporting two (2) investigator initiated studies (numbered
CBPD952AUS05 and CBPD952AUS06) in the QLT Territory which it will continue to support after the
Transition Effective Date. Subject to Section 10.11.6, after the Transition Effective Date,
Novartis shall have the right to continue to invite health practitioners who are based in the QLT
Territory to scientific or medical meetings, symposia, congresses, advisory boards and other
similar events in the Novartis Territory. In addition, Novartis shall have the right to present
and publish any data resulting from the Denali Study, the Mont Blanc Study and the Everest Study in
the QLT Territory. Novartis shall have no other rights to perform development or commercialization
of Visudyne Products in the QLT Territory after the Transition Effective Date. For the avoidance
of doubt, QLT shall not be entitled to receive any data from any of the Mont Blanc, Denali or
Everest studies.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

16

 

Section 4 PDT Devices

	4.1	 	PDT Device Development

On behalf of the Alliance, QLT shall use reasonable efforts to establish strategic alliances with
device companies to jointly develop PDT devices and make them available to the Alliance for
Development Programs prior to the Transition Effective Date.

	4.2	 	Coordination of Marketing and Educational Programs

Novartis acknowledges that QLT has agreed to cooperate with its device alliance partners in the
marketing, education and sales efforts of PDT devices prior to the Transition Effective Date.
Specifically, QLT has agreed to:

4.2.1 use reasonable efforts to cooperate with the device company’s marketing, education and
sales efforts;

4.2.2 treat any marketing plans and sales forecasts of the device company as confidential and
not to disclose such information to any third parties without the prior written consent of the
device company;

4.2.3 make available to the device companies all sales lead and/or product inquires for
Products; and

4.2.4 cooperate in clinical marketing and education to ensure mutual representation at
education programs, medical conferences, workshops and major presentations at leading medical
centres.

	4.3	 	PDT Devices

All costs of the development of PDT devices with device companies will be at QLT’s expense. Costs
related to the acquisition of PDT devices which are necessary for clinical and non-clinical use in
Development Programs prior to the Transition Effective Date will be considered as Development
Expenses as provided for in Section 1.1.18. Upon and after the Transition Effective Date, Novartis
will contract with PDT device companies on its own. QLT will provide Novartis with access to any
future device that QLT may develop on its own or in collaboration with Third Parties for use with
the Visudyne Product in the Novartis Territory, or, if QLT does not have the right to provide such
access in accordance with the terms of its agreement with such Third Party(ies), QLT will use
reasonable efforts to facilitate Novartis’ discussions with such Third Party(ies) regarding
Novartis’ access to such device.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

17

 

Section 5 Joint Coordinating Committee

	5.1	 	Creation of JCC

The parties shall constitute a Joint Coordinating Committee or JCC, consisting of four appointees
from each of QLT and Novartis. The parties shall cause the JCC to meet as soon as is reasonably
possible after the Effective Date. Each party may replace any of its representatives on the JCC,
subject to giving not less than 48 hours notice of such replacement to the other party. If the
appointee of either party is unable to attend a meeting of the JCC, that party may nominate another
person to attend and vote at the meeting in place of the appointee, subject to giving not less than
48 hours notice to the other party.

	5.2	 	Powers of the JCC

The JCC shall manage, or supervise the management of, the business and affairs of the Alliance, the
co-ordination and regulation of the rights and obligations of the parties with respect to this
Agreement, the furnishing and performance of the Work and the distribution of the benefits
therefrom, and without limiting the generality of the foregoing, will have the power to:

5.2.1 approve the Global Development Plan, including estimates of total costs and measures to
protect against cross-sales, and approve revisions to the Global Development Plan annually;

5.2.2 consider, and if satisfied, approve all annual operating budgets, capital plans,
long-range plans and other plans, forecasts and projections for each Development Program presented
to the JCC by the Project Team;

5.2.3 consider, and if satisfied, approve objectives and schedules for each Development
Program set by the Project Team;

5.2.4 consider, and if satisfied, approve Development Programs and any variations, amendments,
suspensions or deletions thereto that may be recommended from time to time by the Project Team;

5.2.5 consider and establish additional Project Teams where appropriate;

5.2.6 review the progress of each Development Program on a Calendar Quarterly basis;

5.2.7 approve the composition of and staffing levels for the Project Team, including the
appointment of the Program Coordinator;

5.2.8 receive proposed Product launch strategies and tactics proposed by Novartis on a
country-by-country or region-by-region basis for Products;

5.2.9 make, amend and repeal from time to time rules and procedures, not inconsistent with the
provisions of this Agreement, to regulate the business and affairs of the Alliance;

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

18

 

5.2.10 give general direction and guidance to the Project Team;

5.2.11 consider, and if satisfied, approve all capital acquisitions and capital projects and
all dispositions of capital assets which individually are estimated to cost or have a value not
exceeding such amount as is from time to time determined by the parties;

5.2.12 establish fiscal and financial policies of the Alliance;

5.2.13 establish accounting procedures and accounting policies applicable to the Alliance;

5.2.14 on behalf of the Alliance and the parties sell, lease or otherwise dispose of equipment
or facilities comprised in the Assets which are being replaced or in the opinion of the JCC are no
longer required for the purpose of the Alliance;

5.2.15 in the names of the Alliance and the parties commence, prosecute or defend any action
or proceeding against or initiated by any person other than the parties pertaining to the Work or
to the business of the Alliance and compromise any claim as they consider in the best interests of
the parties;

5.2.16 carry out such other duties as QLT and Novartis shall mutual agree upon in writing; and

5.2.17 JCC shall have the power to discontinue a Development Program in whole or in part to
address a failure of any Product under Development to meet Acceptable Levels of Efficacy or Safety.

	5.3	 	Decisions of the JCC

No decision will be taken by the JCC at any meeting of the JCC unless the decision is made
unanimously by all appointees present at that meeting.

	5.4	 	Authorities and Rules of Procedure

The conduct of the business and affairs of the Alliance shall be governed by the Authorities and
Rules of Procedure set out in Schedule 5.4, as may be amended from time to time with the unanimous
consent of all appointees to the JCC.

	5.5	 	Delegation by the JCC

The JCC will have the full power and authority to delegate, upon the terms and conditions and
subject to the limitations and restrictions, if any, stipulated by the parties from time to time,
to any Project Team the authority to exercise any of its powers set out in Section 5.2 on behalf of
the JCC.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

19

 

	5.6	 	Chair of the JCC

A Chairperson and a Vice-Chairperson of the JCC shall be appointed annually on a calendar year
basis in alternation between representatives of the parties, starting with QLT having the right to
appoint the Chairperson and Novartis having the right to appoint the Vice-Chairperson for the
remainder of 1994 and for 1995 and vice versa in 1996. The JCC shall appoint a Secretary of the
JCC. The specific duties and responsibilities of the Chairperson, Vice-Chairperson and Secretary
will be established by the JCC.

	5.7	 	Changes in the Role of the JCC After the Transition Effective Date; Primary Contacts

5.7.1 Upon and after the Transition Effective Date, the JCC shall have no further authority
over the development or commercialization of any Product, including but not limited to the Visudyne
Product, and Sections 5.1 through 5.6 shall be of no further force or effect as of the Transition
Effective Date.

5.7.2 Within ten (10) days after the Restatement Date, each party shall appoint one (1)
representative to serve as its primary contact with the other party to coordinate activities under
this Agreement with regard to the Visudyne Product. Such persons shall discuss periodically how to
implement information exchange, reporting and payments under this Agreement and conducting initial
discussions regarding any disputes that may arise out of any ongoing royalty obligations of
Novartis under this Agreement, upon and after the Transition Effective Date.

Section 6 Project Team

	6.1	 	Creation of Project Teams

At the first meeting of the JCC, the JCC will constitute one or more Project Teams, consisting of
an appropriate composition of clinical research, regulatory affairs, preclinical, toxicology,
device development, manufacturing and marketing personnel from among QLT and Novartis.

	6.2	 	Proceedings of Project Teams

The Project Team shall meet at the call of the parties, but not less often than once each Calendar
Quarter, in each case at a mutually convenient location, or, if agreed between the parties, by
video or telephone conference. A quorum for any meeting of the Project Team shall consist of at
least one appointee representing QLT and one appointee representing Novartis.

	6.3	 	Team Leader

Each of Novartis and QLT will appoint one of their appointees of the Project Team acceptable to
both parties, acting reasonably, as their Team Leader, who shall be that parties’ principal contact
person in respect of a Project Team’s Development Program.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

20

 

	6.4	 	Program Coordinator

One of the Team Leaders of either of QLT or Novartis shall be appointed to be the Program
Coordinator of each Development Program, depending upon the phase of the Development Program, or as
otherwise agreed between the parties. Unless the parties expressly agree otherwise, QLT, in
consultation with the JCC, shall appoint a QLT employee as the Program Coordinator of the Project
Team for activities up to the end of phase II clinical studies of any Development Program, and
Novartis, in consultation with the JCC, shall appoint a Novartis employee the Program Coordinator
for activities subsequent to the end of Phase II clinical studies of any Development Program. The
function of the Program Coordinator will be to, in consultation with the other party’s Team Leader,
arrange and chair the necessary meetings of the Project Team and ensure that the Project Team is
performing the functions as set out in Section 6.5.

	6.5	 	Functions of Project Team

The functions of each Project Team shall be to:

6.5.1 prepare the portion of the Global Development Plan applicable to such Project Team’s
Development Program, including estimates of total costs and updating such portion of the Global
Development Plan, as required, on an annual basis for approval by the JCC;

6.5.2 prepare the plans for its Development Program for approval by the JCC;

6.5.3 design, implement, perform and manage each Development Program, including all required
clinical and non-clinical studies, and all regulatory matters and filings on a day-to-day,
month-to-month basis, all as approved by the JCC, under the direction of the Program Coordinator;

6.5.4 form a communications link between the parties with respect to the matters contemplated
by this Agreement;

6.5.5 inform the JCC in advance of significant issues encountered in implementing Development
Programs;

6.5.6 report to the JCC on the progress of Development Programs as requested by the JCC; and

6.5.7 such other duties as the JCC shall deem advisable.

	6.6	 	Prohibited Actions

The Project Team shall not take any action of the general type prohibited by the JCC from time to
time.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

21

 

	6.7	 	Reporting Relationship

The Project Team shall report to the JCC. The Development Program and budgets prepared by the
Project Team shall be submitted to the JCC for approval by the JCC annually, and will be reviewed
by the JCC periodically. In the event of any significant issues or any substantial deviation from
the timelines or any other element of the Global Development Plan or any Development Program, the
Project Team will notify the JCC on a timely basis.

	6.8	 	Changes in Role of Project Teams After the Transition Effective Date

Upon and after the Transition Effective Date, the Project Teams shall have no further authority
with respect to any Products, including but not limited to the Visudyne Product and Sections 6.1
through 6.7 shall be of no further force or effect as of the Transition Effective Date.

Section 7 Personnel

7.1 Allocation of Personnel

Each party reserves the right to determine which of its personnel shall be assigned to perform
under this Agreement, and to replace or reassign such personnel during the term of this Agreement;
provided, however, that it shall:

7.1.1 subject to scheduling and staffing considerations, attempt to honour the reasonable
requests for specific individuals made by the Project Team or the contact person designated
pursuant to Section 5.7; and

7.1.2 maintain the availability of competent personnel acceptable to the other party, acting
reasonably, to the extent necessary to perform its obligations hereunder.

Section 8 License Grants

8.1 Licenses to QLT

8.1.1 Effective as of the Transition Effective Date, and subject to the terms and conditions
of this Agreement, Novartis hereby grants to QLT and its Affiliates an exclusive (even as to
Novartis), fully paid up, royalty free (except as provided in Sections 20 and 27), perpetual
license under the Novartis Technology, to research, develop, use, import, offer for sale and sell
the Visudyne Product in the QLT Territory. This license shall include the right to grant
sublicenses through multiple tiers of sublicensees with the prior written consent of Novartis, such
consent not to be unreasonably withheld. For the avoidance of doubt, QLT shall have the right to
appoint distributors to sell, but not to market or promote the product, without Novartis’ prior
written consent. QLT shall also be entitled to engage a contract sales force to sell Visudyne
Product on its behalf without the prior written consent of Novartis, provided that does not include
a co-promotion, co-marketing or other similar arrangement with a Third Party. QLT

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

22

 

shall have the right to grant to any such distributors or contract sales force providers a
sublicense under this Section 8.1.1 to the extent necessary to enable such Third Party to conduct
such activities.

8.1.2 Effective as of the Transition Effective Date, and subject to the terms and conditions
of this Agreement, Novartis hereby grants to QLT and its Affiliates a non-exclusive, fully paid up,
royalty free (except as provided in Sections 20 and 27), perpetual license under the Novartis [*]
Patents, to research, develop, use, import, offer for sale and sell the Visudyne Product in the QLT
Territory. This license shall include the right to grant sublicenses through multiple tiers of
sublicensees with the prior written consent of Novartis, such consent not to be unreasonably
withheld. For the avoidance of doubt, QLT shall have the right to appoint distributors to sell,
but not to market or promote the product, without Novartis’ prior written consent. QLT shall also
be entitled to engage a contract sales force to sell Visudyne Product on its behalf without the
prior written consent of Novartis, provided that does not include a co-promotion, co-marketing or
other similar arrangement with a Third Party. QLT shall have the right to grant to any such
distributors or contract sales force providers a sublicense under this Section 8.1.2 to the extent
necessary to enable such Third Party to conduct such activities.

8.1.3 Effective as of the Transition Effective Date, and subject to the terms and conditions
of this Agreement, Novartis hereby grants to QLT and its Affiliates an exclusive (even as to
Novartis), fully paid up, royalty free, perpetual license to use and publicly display the Visudyne
Trademark, including the domain name “Visudyne.com”, solely to sell, promote, market and otherwise
commercialize the Visudyne Product in the QLT Territory for indications for which the FDA has
granted or may grant in the future regulatory approval in the Field. This license shall include the
right to grant sublicenses through multiple tiers of sublicensees with the prior written consent of
Novartis, such consent not to be unreasonably withheld, except that QLT may grant sublicenses under
this Section 8.1.3 without the prior written consent of Novartis to the extent necessary to allow
the distributors and contract sales force providers to conduct activities as permitted pursuant to
Section 8.1.1, and to allow manufacturers of the Visudyne Product to conduct their obligations as
permitted pursuant to Section 8.1.4. QLT undertakes not to use the Visudyne Trademark outside of
the QLT Territory or in the QLT Territory outside the Field, except to the extent necessary to
engage subcontractors to manufacture the Visudyne Product for QLT in accordance with the license
granted to QLT in Section 8.1.4.

8.1.4 Effective as of the Transition Effective Date, and subject to the terms and conditions
of this Agreement, Novartis hereby grants to QLT and its Affiliates a nonexclusive, fully paid up,
royalty free, perpetual license under the Novartis Technology, to make and have made the Visudyne
Product anywhere in the Territory for the purpose of exercising its rights and performing its
obligations under this Agreement. This license shall include the right to grant sublicenses
through multiple tiers of sublicensees with the prior written consent of Novartis, such consent not
to be unreasonably withheld, except that QLT shall be entitled to appoint a sub-contractor for the
manufacture of the Visudyne Product without the prior written consent of Novartis, and to grant
such subcontractor a sublicense under this Section 8.1.4 to the extent necessary to allow such
subcontractor to perform such activities; provided that QLT will include in any Agreement with such
subcontractor a license allowing QLT itself, and Novartis as

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

23

 

sublicensee of QLT, to practice any intellectual property rights created by such subcontractor
that are necessary or useful for manufacturing the Visudyne Product; provided that the foregoing
shall not obligate QLT or such subcontractor to transfer technology or otherwise enable the
practice of such license, other than expressly provided for under this Agreement.

	8.2	 	Licenses to Novartis

8.2.1 Subject to the terms and conditions of this Agreement, QLT hereby grants to Novartis and
its Affiliates an exclusive (even as to QLT), royalty bearing, perpetual license under the QLT
Technology, to research, develop, use, import, offer for sale and sell the Visudyne Product in the
Field in the Novartis Territory. This license shall include the right to grant sublicenses through
multiple tiers of sublicensees. Additionally, effective as of the Transition Effective Date, and
subject to the terms and conditions of this Agreement, QLT hereby grants to Novartis and its
Affiliates a non-exclusive, royalty bearing, perpetual license under the QLT Technology, to make
and have made the Visudyne Product anywhere in the world solely for the purpose of exercising its
rights under this Agreement, subject to QLT’s right to be the sole supplier of the Visudyne Product
as set forth in Section 9.6.1. The foregoing license and sublicensing rights are, as to rights
granted to QLT pursuant to the UBC Agreement and the MGH Agreement that are sublicensed to Novartis
pursuant to this Section 8.2, limited to the scope of the rights granted to QLT pursuant to such
agreements. QLT may agree to amend the UBC Agreement or the MGH Agreement in any way; [*].
Novartis’ obligation to pay Third Party Royalties, or any other amount to QLT in respect of the [*]
is limited to the obligations contained at [*] of this Agreement. QLT covenants to observe the
terms of the UBC Agreement and the MGH Agreement [*] Novartis [*] that does [*] with the terms and
conditions of this Agreement.

8.2.2 Effective as of the Transition Effective Date, and subject to the terms and conditions
of this Agreement, QLT hereby grants to Novartis and its Affiliates a non-exclusive,
royalty-bearing, perpetual license under the QLT [*] Patents to research, develop, use, import,
offer for sale and sell the Visudyne Product in the Field in the Novartis Territory. Additionally,
effective as of the Transition Effective Date, and subject to the terms and conditions of this
Agreement, QLT hereby grants to Novartis and its Affiliates a non-exclusive, royalty bearing,
perpetual license under the QLT [*] Patents, to make and have made the Visudyne Product anywhere in
the world solely for the purpose of exercising its rights under this Agreement, subject to QLT’s
right to be the sole supplier of the Visudyne Product as set forth in Section 9.6.1. These
licenses shall include the right to grant sublicenses through multiple tiers of sublicensees.

	8.3	 	No Implied Rights

This Agreement confers no right, license, or interest by implication, estoppel, or otherwise under
any Patents, Proprietary Information, or other intellectual property rights of either party except
as expressly set forth in this Article 8 and Articles 24 and 25. Each party hereby expressly
retains and reserves all rights and interests with respect to its Patents, Proprietary Information,
or other intellectual property rights not expressly granted to the other party hereunder.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

24

 

Section 9 Manufacturing

	9.1	 	Responsibility for Product Manufacturing

The manufacture of Products shall be the responsibility of the Drug Owner.

Towards Third Parties, including governmental authorities, Drug Owner shall be responsible for
manufacture of the Product in compliance with Applicable Law in the Territory. Novartis shall
inform QLT of any filings or other communications with applicable health or other governmental
authorities that are required for the manufacture of the Visudyne Product in compliance with
Applicable Law after the Transition Effective Date, other than those requirements applying prior to
the Restatement Date. Novartis shall use commercially reasonable efforts to minimize the impact
that any such requirements will have upon the manufacture of the Visudyne Product within the
requirements of Applicable Law.

	9.2	 	Subcontractors

The Drug Owner may contract to Third Parties for the manufacturing of Products. The Drug Owner
shall be responsible for the identification and qualification of any such manufacturer for the
Products of the Drug Owner, provided that the Drug Owner gives advance written notice to the other
party of the selection of such manufacturer by the Drug Owner, and the Drug Owner shall indemnify
and hold harmless the other party for the performance of the manufacturer.

	9.3	 	Production Efforts

Each party shall ensure that sufficient quantities of Product for which that party is responsible
are available in unlabelled finished single dosage form for non-clinical and clinical studies as
part of relevant Development Programs and in adequately identified (but not necessarily labelled)
finished single dosage form for commercial distribution.

	9.4	 	Manufacture of Products

Each party covenants with and represents and warrants to the other party with respect to each of
the Products for which such party is responsible that each such Product shall be manufactured:

9.4.1 in conformance with all applicable registration applications submitted to all regulatory
bodies, and all supplements and amendments thereto;

9.4.2 in accordance with all Applicable Law of any jurisdiction in which such Products are to
be distributed of which such party has been informed, including current GMP regulations which are
in force or are hereafter adopted by relevant regulatory bodies;

9.4.3 to meet the specifications therefor submitted to any regulatory agency having
jurisdiction over such Products and will not be adulterated and misbranded within the meaning of
the FDCA (U.S. Food, Drug and Cosmetics Act) or any corresponding provisions of any

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

25

 

applicable state, foreign or municipal laws in which the definition of adulteration or
misbranding are substantially the same as in the FDCA; and

9.4.4 shall be merchantable and fit for the purposes for which intended as specified in the
applicable regulatory approval.

	9.5	 	Management of Samples

The parties shall cooperate with each other to permit each other to provide Product for phase IV
studies, samples and compassionate use programs. The parties will consider requests from
researchers and investigators and, on a reasonable basis, provide them with Product free of charge
and at the parties’ shipping expense with Product for non-commercial use by such researchers and
investigators.

	9.6	 	Manufacture of Visudyne Product After the Transition Effective Date

Upon and after the Transition Effective Date and for the remainder of the term of this Agreement,
the following will apply with respect to the manufacturing of the Visudyne Product.

9.6.1 As the Drug Owner for the Visudyne Product, QLT will continue to manufacture or have
manufactured and supply to Novartis the finished unlabelled Visudyne Product, in accordance with
the specifications for the Visudyne Product in existence as of the Transition Effective Date and
any additional specifications as may be required by a Regulatory Authority for the time being and
from time to time, for development and commercialization in the Novartis Territory, subject to the
terms and conditions of this Section 9.6. QLT will supply Visudyne Product for development and
commercialization in the Novartis Territory exclusively to Novartis, and Novartis will purchase the
Visudyne Product for such purposes in the Novartis Territory solely from QLT, subject to Novartis’
backup rights to manufacture the Visudyne Product as described in Section 9.6.2.

9.6.2 The parties will enter into a manufacturing and supply agreement (“MSA”) prior to the
Transition Effective Date for the supply of the Visudyne Product by QLT to Novartis for the
Novartis Territory. The MSA will be consistent with this Section 9.6, and will include terms
typically contained in agreements for supply of similar products for similar purposes, including
but not limited to terms relating to manufacturing specifications, forecasts, shipment, transfer
price, acceptance and rejection after receipt of shipments, quality standards, Novartis’ back-up
rights to manufacture Visudyne Product for the Novartis Territory in the event of a breach of the
MSA by QLT, allocation of resources in the event that manufacturing capacity is limited, second
site manufacturing rights, audit rights, and procedures for recalls and interactions with
regulatory authorities, change control, but excluding any technology transfer, know-how or the
enablement of manufacture for the Visudyne Product after the termination of this Agreement pursuant
to Section 27. The term of the MSA shall continue until December 31, 2019, unless Novartis gives
prior written notice of termination as permitted in this Agreement.

9.6.3 Pursuant to the MSA, Novartis will pay to QLT a transfer price for the finished Visudyne
Product of (i) [*] per vial for Visudyne Product shipped to Novartis or its designee at a

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

26

 

single location identified by Novartis during the period commencing on the Transition
Effective Date until and including [*], and (ii) [*] for Visudyne Product shipped to Novartis or
its designee at a single location identified by Novartis during the period [*] during the remainder
of the term of the MSA.

9.6.4 QLT shall be responsible for the costs of [*] in the [*] period which ended on [*] in
the amount of [*].

9.6.5 The MSA shall require Novartis to submit to QLT, on a Product-by-Product basis, by the
tenth (10th) Business Day after the end of each Calendar Quarter, a twelve (12) month rolling
quarterly forecast of the quantities of Visudyne Product that Novartis intends to order from QLT
during the twelve (12) month period commencing upon the first day of the Calendar Quarter following
that in which such forecast is submitted. All such forecasts shall be non-binding and used for
planning purposes only, subject to other terms and conditions set forth in this Article 9.

9.6.6 Commencing upon the date upon which the MSA becomes effective, Sections 9.1 through 9.5
shall be of no further force or effect as of the Transition Effective Date.

9.6.7 Within thirty (30) days after the Transition Effective Date, Novartis shall transfer to
QLT any and all inventory of labeled finished Visudyne Product packaged for the QLT Territory then
physically located in the QLT Territory or intended for supplying Visudyne Product in the QLT
Territory prior to the Transition Effective Date. QLT shall re-label any of such Visudyne Product
which has not been sold within six (6) months of the Transition Effective Date. QLT shall pay for
any such inventory at the cost at which Novartis acquired such inventory (including packaging
costs). Novartis shall submit an invoice to QLT in respect of such inventory. Payment terms are
thirty (30) days from the date of the invoice.

Section 10 Marketing and Distribution

	10.1	 	Distribution by Novartis

Except as otherwise noted in this Section 10, Novartis shall have the exclusive right to
distribute, or, in any country where Novartis or any of its Affiliates does not have a direct sales
or distributorship capability, have distributed, all Products in the Field within the Territory
under this Agreement. A listing of the countries in the Territory for which Novartis and its
Affiliates as at the Effective Date have direct sales and distributorship capabilities is attached
as Schedule 10.1 to this Agreement. In the event that Novartis grants or sublicenses marketing
rights to any Third Party in any country or region in the Territory, Novartis will inform QLT of
the identity of such Third Party within a reasonable time period and provide QLT with copies of any
written arrangements or understanding between Novartis and such Third Party.

	10.2	 	Market Studies

Novartis will conduct reasonable market research in accordance with its normal practices prior to
the launch of commercial sales of each Product and shall provide to QLT upon its general

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

27

 

request through the JCC copies of all market research, whether purchased externally or generated
internally by Novartis personnel, prior to launch of each Product.

	10.3	 	Product Pricing

Novartis shall have responsibility for establishment of the recommended list price for each Product
and the determination of any rebates, allowances or volume discounts to end users. Novartis shall
be responsible for obtaining any pricing approvals required from government agencies prior to
commercial sale of any Products. Novartis shall inform QLT of all pricing decisions, and, upon the
reasonable request of QLT, provide copies of any pricing studies conducted for any Products.

	10.4	 	Marketing

Novartis will undertake the sales, marketing, advertising and sales promotion of Products in the
Territory. Upon the reasonable request of QLT, Novartis shall submit a marketing plan to the JCC
for each Product in each region or country in the Territory within a reasonable time after
regulatory approval of such Product in such region or country. Novartis will conduct all sales,
marketing, advertising and sales promotion activities in accordance with Applicable Law, including
those relating to labeling and promotional literature. Upon the reasonable request of QLT,
Novartis shall provide to QLT with all sales reports or updates produced by Novartis or Affiliates
regarding Products.

	10.5	 	Product Labelling and Literature

Products will be promoted and marketed identifying the Drug Owner as the manufacturer of the
Product on the label and the package design, which shall be in compliance with local laws and
regulations.

	10.6	 	Sales Reports

Within forty-five (45) days of the end of each Calendar Quarter, Novartis shall give QLT a
quarterly report of Net Sales by Novartis of all Products, including a breakdown of such Net Sales
by country, number of units and price.

	10.7	 	Marketing Obligations

Novartis shall use reasonable efforts, consistent with Novartis’ reasonable judgement as to the
commercial potential for the Products and Novartis’ over-all business and marketing plans for its
medical business, to promote and increase sales of the Products.

	10.8	 	Option to Distribute

In the event that Novartis fails to notify QLT within one hundred and eighty (180) days of the date
of receipt of the final regulatory or pricing approval that is reasonably required to commercially
market and sell a Product in a particular country that Novartis intends to market

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

28

 

and distribute such Product in such country, then QLT, at QLT’s option, shall be appointed the
exclusive distributor of such Product in such country in perpetuity, with a right to appoint
subdistributors, with a payment to Novartis of a commercially reasonable royalty based on the Net
Sales of such Product in such country and on such other terms as are then reasonably standard for
the distribution of pharmaceuticals at the time of such appointment, as agreed to between the
parties, acting reasonably. If the parties fail to agree on such amount, then the matter may be
referred to arbitration by either party for a determination in accordance with Section 29.2.

	10.9	 	Return of Rights

In the event that QLT believes that Novartis has failed to make a good faith effort to market a
Product in accordance with Novartis’ normal practices and standards in a given country (generally
referred to as a “good faith marketing effort”), and Section 10.8 does not apply, upon not less
than 120 days notice, QLT may refer the matter to arbitration for a determination in accordance
with Section 29.2. Upon any determination by arbitration under Section 29.2 that Novartis has
failed to make a good faith marketing effort in a country, QLT and Novartis shall transfer the
marketing rights for such Product in that country to a third party distributor to be mutually
agreed upon provided that any proceeds received from such third party distributor shall be shared
between QLT and Novartis consistent with the terms of this Agreement.

	10.10	 	Co-Promotion

In the event that QLT and Novartis believe that a greater marketing effort than the effort put
forth by Novartis for any Products is justified in any country in the Territory, then, on notice
from QLT, Novartis shall offer to QLT the right to co-promote, but not the right to sell, such
Products in such country, at QLT’s expense, on such profit sharing and other terms as are then
reasonably standard for the distribution of pharmaceuticals at the time of such appointment, as
agreed to between the parties, acting reasonably. If the parties fail to agree on such amount,
then the matter may be referred to arbitration by either party for a determination in accordance
with Section 29.2.

	10.11	 	Marketing and Distribution After the Transition Effective Date

Upon and after the Transition Effective Date and for the remainder of the term of this Agreement,
the following will apply with respect to the marketing and distribution of the Visudyne Product in
the QLT Territory and the Novartis Territory. Sections 10.1 through 10.10 shall be of no further
force or effect as of the Transition Effective Date.

10.11.1 Distribution. Except as otherwise noted in this Section 10, each party shall have the
exclusive right to distribute, or, in any country where such party or any of its Affiliates does
not have a direct sales or distributorship capability, have distributed at such party’s expense,
all Visudyne Products in the Field within its respective territory under this Agreement (i.e., QLT
shall have such right in the QLT Territory and Novartis shall have such right in the Novartis
Territory). A listing of the countries in the Novartis Territory for which Novartis and its
Affiliates currently have direct sales and distributorship capabilities is attached

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

29

 

as Schedule 10.1 to this Agreement. Subject to any provisions of the Agreement requiring
consent to sub-licensing or subcontracting, in the event that a party grants or sublicenses
marketing rights to any Third Party in any country or region in its respective territory, such
party will inform the other party of the identity of such Third Party within a reasonable time
period.

10.11.2 Product Pricing. Each party shall have responsibility for establishment of the
recommended list price for the Visudyne Product and the determination of any rebates, allowances or
volume discounts to end users in its respective territory, and each party shall be responsible for
obtaining any pricing approvals required from government agencies prior to commercial sale of
Visudyne Product in its respective territory.

10.11.3 Marketing. Novartis will undertake the sales, marketing, advertising and sales
promotion of Visudyne Product in the Novartis Territory in accordance with Applicable Law,
including those relating to labeling and promotional literature.

10.11.4
Sales Reports. Within [*] Business Days after the end of each Calendar Quarter,
Novartis shall give QLT a quarterly report of Net Sales by Novartis, its Affiliates and
sublicensees of all Visudyne Product, as recorded in Novartis’ financial reporting systems,
including a breakdown of such Net Sales by country in both US dollars and in local currency, and
the number of units of Visudyne Product sold during such Calendar Quarter in each country. In
addition to such quarterly reports, Novartis shall also provide to QLT for the Visudyne Product in
the Novartis Territory the royalty reports as set forth in Section 20, copies of the annual sales
budget for each year, at the end of such year for the following year, as well as a mid-year
forecast update each year.

10.11.5 Marketing Obligations. Novartis shall use reasonable efforts, consistent with its
reasonable judgment as to the commercial potential for the Visudyne Products in the Novartis
Territory and its over-all business and marketing plans for its medical business, to promote,
market and sell the Visudyne Product in the Novartis Territory. In the event that QLT [*] are being
made in accordance with [*], then the parties will meet to discuss in good faith the steps that
reasonably [*]. Novartis acknowledges that its obligations under this Section 10.11.5 shall comply
with applicable [*].

10.11.6 Promotion. Neither party shall undertake the sales, marketing, advertising and sales
promotion of the Visudyne Product in the other party’s territory, or the promotion of the Visudyne
Product to healthcare practitioners from the other party’s territory, without the prior written
consent of the other party, provided that each party shall be free to invite healthcare
practitioners from such party’s territory to congresses and other similar scientific meetings which
take place in the other party’s territory. For the avoidance of doubt, nothing shall prevent
healthcare practitioners from a party’s territory from presenting data from clinical trials related
to the Visudyne Product in the other party’s territory, in accordance with applicable local laws,
rules and regulations. Each party shall use reasonable efforts to inform the other about such
events in advance of the presentation, to the extent such party is aware of them. QLT will not,
either by itself or through a third party (other than Novartis) carry out any promotional
activities prior to the Transition Effective Date. After the Transition Effective Date,
Novartis will be

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

30

 

responsible for its promotional and field sales force expenses with regard to
the Visudyne Product in the Novartis Territory and QLT will be responsible for its promotional and
field sales force expenses with regard to the Visudyne Product in the QLT Territory. For the
avoidance of doubt, nothing shall operate to prevent or restrict Novartis from continuing to have
access to clinical sites, other healthcare institutions and healthcare practitioners based in the
QLT Territory for its other ophthalmic products and businesses. For clarity, QLT will not itself
or through Third Party(ies), promote the Visudyne Product in North America prior to the Transition
Effective Date and [*].

10.11.7 Inventory. Novartis agrees to use reasonable efforts to ensure that distributor
inventory levels for the Visudyne Product held as of [*] do not increase beyond the average year
end inventory levels of the Visudyne Product maintained during the [*].

10.11.8 Trademark. During the term of this Agreement, Novartis shall sell the Visudyne
Product only under the Visudyne Trademark in the Novartis Territory.

10.11.9 Website. Effective as of the Transition Effective Date, Novartis shall, and hereby
grants rights solely to QLT to amend, maintain, update and create web content and information
(“Web Content Rights”) in QLT’s sole and exclusive discretion on the website at the URL
www.visudyne.com, including all internal links off such site (“Web Site”), provided that QLT shall
be solely responsible for any content on the Web Site and the indemnities set forth in 23.7.2.2
shall apply to any loss or damage suffered by Novartis arising as a result of such content. At no
additional cost to QLT, Novartis shall continue to maintain the domain name server to which QLT
shall have the right to link the Web Site in accordance with the Novartis domain name policy. QLT
shall not acquire any rights to either the Visudyne Trademark or the Web Site domain name, except
as provided in this Agreement. QLT hereby agrees to observe and perform all of the duties,
obligations, terms, provisions and covenants set out in Section 12 of this Agreement, applicable to
the use of the Visudyne Trademark on the Web Site and to cooperate with Novartis in any content
modification, links or editorial updates regarding Visudyne domain names other than
www.visudyne.com and relating to the Novartis Territory. The parties will cooperate to transition
the Web Content Rights to QLT so as to enable QLT to assume full responsibility as soon as
reasonably practicable and in any event within thirty (30) days of the Transition Effective Date.

10.11.10 QLT Decision to Cease Commercialization. If QLT, its Affiliates and sublicensees all
decide to Cease to Commercialize the Visudyne Product in the QLT Territory, Section 27.7.2 shall
apply to allow Novartis to elect to commercialize the Visudyne Product in the QLT Territory.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

31

 

Section 11 Regulatory Approvals

	11.1	 	Regulatory Approvals

11.1.1 In respect of any Products, the relevant Project Team shall assume responsibility for
compiling a Basic International Registration Documentation (“BIRD”) according to Schedule 11.1.1.

11.1.2 The JCC shall have the responsibility to decide which party takes over the
responsibility to submit the registration dossier in a country of the Territory according to the
local regulations.

11.1.3 The submissions shall be made in each country of the Territory which the JCC
determines. In the event any party wishes to make a submission for regulatory approval for a
Product in a country that the JCC has determined not to make a submission for regulatory approval
and the JCC agrees that such party may make such submission, that party may proceed at its cost to
make the submission on behalf of the Alliance and, if regulatory approval is granted in such
country, the party which funded the full cost of the submission shall be entitled to such
compensation as the JCC determines is appropriate in the circumstances, acting reasonably.

11.1.4 Except as prohibited by law or upon agreement of QLT and Novartis, the Drug Owner shall
be the owner of any registration approval application thereby obtained. If a party other than the
Drug Owner is identified on any registration approval application, such party shall be deemed to
hold such approval in trust on behalf of the Drug Owner and will take all reasonable steps to
protect the interests of the Drug Owner, and take whatever steps are necessary to effectively
assign or transfer such approval at the request of the Drug Owner.

11.1.5 The submitting party shall have the responsibility to respond on behalf of the Alliance
to any request for additional information and tests required by the local health authorities. The
costs which occur thereunder shall be considered to be Development Expenses and shall be shared
according to the Funding Formula as set out in Section 15.2.

11.1.6 Each party shall advise the other, on a timely basis, of any regulatory notices,
actions or communications relating to any Products.

	11.2	 	Regulatory Responsibility

The Drug Owner shall be responsible, at its own expense, for all registrations required by a
regulatory agency or government for the manufacturing location of the Products.

	11.3	 	Responsibility for Books and Records

In respect of each Product, the Drug Owner shall maintain adequate books and records as required by
the applicable boards of health and shall comply with all Applicable Law. Without limiting the
generality of the foregoing, each party agrees to comply and have its contractors

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

32

 

comply with current GMP, GCP, and GLP regulations which are in force or are hereafter adopted by
any relevant regulatory authorities.

	11.4	 	Notice of Findings

Each party will promptly notify the other party in writing of any significant unusual
physiochemical, pharmacological, toxicological or pharmacokinetic finding from experiments and/or
clinical studies with Product.

	11.5	 	Recall

The parties shall immediately contact each other in the event that either party has reason to
believe that the recall of the Product may be necessary. The parties shall fully cooperate and
shall resolve any issues with respect to the recall of any such Product including without
limitation, the necessity of declaring the recall, the manner in which the recall should be
conducted and the duration of the recall. All related costs of the administering the recall and
for loss of inventory as a result of such recall, the replacement of Product to Novartis or
credited to Novartis’ customers by Novartis and for Product involved in such recall and incurred in
the result of an injunction, seizure or stop sale shall be deemed to be Marketing and Distribution
Expenses and subject to allocation of Net Proceeds in accordance with Section 19. This Section
shall have no effect on each party’s obligations under Sections 9, 23.5 and 23.6 under this
Agreement.

	11.6	 	Regulatory Approvals for Visudyne Product After the Transition Effective Date

Upon and after the Transition Effective Date and for the term of this Agreement, the following
shall apply with regard to regulatory approvals for the Visudyne Product and Sections 11.1 through
11.5 shall be of no further force or effect as of the Transition Effective Date:

11.6.1 Regulatory Approvals. In respect of the Visudyne Product, QLT shall assume
responsibility, at its expense, for all filings with regulatory authorities with respect to the
Visudyne Product in the QLT Territory, and Novartis shall assume responsibility, at its expense,
for all filings with regulatory authorities with respect to the Visudyne Product in the Novartis
Territory (subject to QLT’s obligations under Article 9 and any MSA). Except as prohibited by
Applicable Law QLT shall be the owner of any registration approval application thereby obtained in
the QLT Territory and Novartis shall be the owner of any registration approval application thereby
obtained in the Novartis Territory. The owning party shall have the responsibility to respond to
any request for additional information and tests required by the local health authorities. Each
party shall advise the other, on a timely basis, of any regulatory notices, actions or
communications relating to the Visudyne Product that could materially and adversely affect the
Visudyne Product in such other party’s territory.

11.6.2 Regulatory Responsibility. QLT shall be responsible, at its own expense, for all
registrations required by a regulatory agency or government for the manufacturing location of the
Visudyne Product.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

33

 

11.6.3 Responsibility for Books and Records. Each party shall maintain adequate books and
records for Visudyne Product in its respective territory, as required by the applicable boards of
health and shall comply with all Applicable Laws. Without limiting the generality of the
foregoing, each party agrees to comply and have its contractors comply with current GMP, GCP, and
GLP regulations which are in force or are hereafter adopted by any relevant regulatory authorities
applicable to Visudyne Product.

11.6.4 Notice of Findings. Each party will promptly notify the other party in writing of any
significant unusual physiochemical, pharmacological, toxicological or pharmacokinetic finding from
experiments and/or clinical studies with Visudyne Product after the Transition Effective Date.

11.6.5 Recall. The parties shall immediately contact each other in the event that either
party has reason to believe that the recall of the Visudyne Product may be necessary. The parties
shall fully cooperate in connection with such matter provided that QLT shall have the right to make
a final determination of whether to conduct such recall in the QLT Territory, and Novartis shall
have the right to make a final determination of whether to conduct such recall in the Novartis
Territory. All related costs of the administering of the recall and for loss of inventory as a
result of such recall [*] shall be borne by [*] to the extent the recall arises from [*]. QLT
shall replace any such defective Visudyne Product or, at Novartis’ sole discretion, any batch
containing such defective Visudyne Product, with conforming Visudyne Product or conforming batch of
Visudyne Product, as the case may be, [*]. QLT shall use commercially reasonable efforts to
complete such replacement within [*] of Novartis’ notification. All related costs of the
administering of the recall and for loss of inventory as a result of such recall [*] and such [*].
Except as otherwise provided in this Section 11.6.5, Novartis [*]. This Section shall have no
effect on each party’s obligations under Sections 9, 23.7.1 and 23.7.2 under this Agreement.

Section 12 Trademarks

	12.1	 	Novartis to Select Trademarks

Novartis, as it deems appropriate, shall originate, select and apply to register one or more
trademarks under which the Products shall be sold and distributed by Novartis, provided that
Novartis shall notify QLT prior to their selection of such trademarks and take into account QLT’s
comments regarding same. Novartis agrees not to market any Product under a trademark which is
confusingly similar to or incorporates the whole of any trademark of Novartis existing at the time
a trademark for a Product is selected. Novartis shall be solely responsible for all prosecution,
defence, maintenance and costs relating to all such trademarks and all decisions relative to all
such trademarks shall be made by Novartis as the trademark owner.

	12.2	 	Control of Trademarks

QLT shall bear no responsibility for any of the costs and efforts associated with the selection,
searching, registration, licensing and protection of such trademarks. QLT shall not use, or assert
any claim in, any of such trademarks owned by Novartis or in any trademark confusingly similar to
any of such trademarks either during or, unless QLT has succeeded to the ownership of any

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

34

 

such trademark, after the expiration or termination of this Agreement nor utilize any trademark
licensed to Novartis hereunder, while such license is in effect, in any manner so as to cause
confusion with any Products or as to the identity of any marketer thereof.

	12.3	 	Review of Trademarks

Upon QLT’s reasonable request from time to time, Novartis shall provide to QLT for review, copies
of all packaging, promotional material and advertising which it shall intend to use that refers to
QLT, BPD or any Additional Photosensitizer of QLT. At QLT’s reasonable request, Novartis shall
refer to the Products of QLT in such literature by the QLT trademark that QLT indicates is
appropriate, and use such trademarks in a manner consistent with QLT style guidelines for the use
of same, as amended from time to time. Novartis shall include on material bearing such trademarks
an acknowledgement that such trademarks are the property of QLT. If necessary in any market to
maintain QLT’s rights in any QLT trademarks, Novartis shall enter into a registered user agreement
regulating its use of such QLT trademarks.

	12.4	 	Trademarks for Product After the Transition Effective Date

12.4.1 Upon and after the Transition Effective Date, Sections 12.1 through 12.3 shall cease to
apply as to any of the parties’ trademarks, except that such Sections shall continue to apply to
the Visudyne Trademark after the Transition Effective Date, subject to Section 12.4.2.

12.4.2 As set forth in Section 10.11.8, upon and after the Transition Effective Date, and
during the term of this Agreement, Novartis shall sell the Visudyne Product only under the Visudyne
Trademark in the Novartis Territory. Upon and after the Transition Effective Date, QLT will sell
the Visudyne Product only under the Visudyne Trademark in the QLT Territory. QLT will not affix or
use any other trademark on or in connection with the Visudyne Product, however QLT may use its
trade name on packaging, leaflets, advertising and promotional materials for the Visudyne Product
upon and after the Transition Effective Date.

12.4.3 Upon and after the Transition Effective Date, QLT shall have a royalty-free, fully paid
right to use the Visudyne Trademark in connection with the Visudyne Product in the QLT Territory as
set forth in Section 8.1.3. QLT shall use such trademark in a manner consistent with Novartis
style guidelines for the use of same, as amended from time to time. QLT shall include on material
bearing such trademark an acknowledgement that such trademark is the property of Novartis. Upon
Novartis’ reasonable request from time to time, QLT shall provide to Novartis for review, copies of
all packaging, promotional material and advertising which it shall intend to use that refers to the
Visudyne Trademark so that Novartis may confirm QLT’s compliance with this Section 12.4.

12.4.4 Upon and after the Transition Effective Date, Novartis shall be responsible for
registering, and shall maintain, the Visudyne Trademark in the QLT Territory for as long as the
Visudyne Product is sold in the QLT Territory, at its own expense. QLT shall cooperate with
Novartis, in the preparation, execution or recording of any documents necessary to register or
otherwise protect the Visudyne Trademark in the QLT Territory.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

35

 

12.4.5 Novartis will maintain the Visudyne Trademark in the Novartis Territory, at its own
expense.

12.4.6 Either party shall notify the other party in writing promptly upon learning of any
actual, alleged or threatened infringement of the Visudyne Trademark or of any unfair trade
practices, trade dress imitation, passing off of counterfeit goods, or like offenses, against the
Visudyne Trademark by a Third Party, identifying in such notice the alleged infringer and the
alleged infringement complained of and furnishing the information upon which such determination is
based. Novartis shall have the first right, but not the obligation, through counsel of its
choosing and at its expense, to take any measures it deems appropriate to stop such infringing
activities by such Third Party in the QLT Territory. Upon reasonable request by Novartis, QLT
shall give Novartis all reasonable information and assistance, and, if necessary for Novartis to
prosecute any legal action, joining in the legal action as a party at Novartis’ expense. QLT shall
have the right to participate and be represented in any such action by its own counsel and its sole
cost and expense without reimbursement hereunder. If QLT elects to so participate or be involved,
Novartis shall provide QLT and its counsel with an opportunity to consult with Novartis and its
counsel regarding the prosecution of such action (including reviewing the contents of any
non-privileged correspondence, legal papers or other documents related thereto). In the event
Novartis fails within two (2) months following notice of such infringement, or earlier notifies QLT
in writing of its intent not to take commercially appropriate steps to remove any infringement of
the Visudyne Trademark then QLT shall have the right, but not the obligation, to do so at QLT’s
sole cost and expense. Upon reasonable request by QLT, Novartis shall give QLT all reasonable
information and assistance in connection with such suit for infringement at QLT’s expense.

Section 13 Mandatory Right of First Refusal on Additional Photosensitizers

	13.1	 	RFR Notice

During the term of this Agreement, each party will promptly notify the other through the JCC of any
opportunities in the Field for the development or commercialization of any Photosensitizer other
than BPD or ZnPc that such party may have developed, licensed, acquired or otherwise has commercial
access (which notice is hereinafter called the “RFR Notice”).

	13.2	 	Terms of RFR Notice

The RFR Notice shall state a reasonably clear and complete description of the opportunity for such
Photosensitizer, and the terms on which each party offers the opportunity to exploit such
Photosensitizer, including all monetary and all other material terms, all of which terms shall be
consistent with the terms of this Agreement.

	13.3	 	Proof of Principle Required

The RFR Notice shall also be accompanied by sufficient preliminary testing of the Photosensitizer
to establish the proof of principle for the Photosensitizer in the Field.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

36

 

	13.4	 	Acceptance Notice

Upon receipt of the RFR Notice, the other party may elect to extend the terms of this Agreement to
include the development and commercialization of such Photosensitizer within the Field by
delivering to the party giving such notice of its intention to do so within sixty (60) days
following receipt by the other party of the RFR Notice (which notice is hereinafter called the
“Acceptance Notice”).

	13.5	 	Agreement with Third Parties

If the other party fails to deliver the Acceptance Notice in the time period set out in Section
13.4, then the party wishing to commercialize such Photosensitizer in the Field may offer and agree
with any other party for the commercialization of same on terms and conditions no more favourable
than those set out in the RFR Notice.

	13.6	 	Mandatory Right of First Refusal on Additional Photosensitizers After the Transition
Effective Date

Notwithstanding Section 13.1 through 13.5, upon and after the Transition Effective Date the
mandatory right of first refusal pursuant to this Section 13 shall be of no further force or
effect. The parties further acknowledge that there has been no development of Additional
Photosensitizers prior to the Transition Effective Date.

Section 14 Right of First Option to Commercialize

Verteporfin in Certain PDT Dermatology Fields

	14.1	 	Option Field

As used in this Section 14 “Option Field” will mean the use of Verteporfin in PDT for the
treatment, prevention or diagnosis of any dermatological condition excluding the treatment,
prevention or diagnosis of dermatological tumors. For greater certainty, dermatological tumors
include all forms of non-melanoma skin cancer, including multiple basal cell carcinoma, and such
conditions are outside of the Option Field. Novartis will have no rights or entitlements
whatsoever with respect to any existing or future development programs or the marketing and sale of
Verteporfin for the treatment, prevention or diagnosis of dermatological tumors.

	14.2	 	Option Notice

14.2.1 At least 60 days prior to the date that QLT anticipates holding an end of phase II
clinical trial meeting with the FDA with respect to any phase II clinical trials conducted by QLT
with respect to the use of Verteporfin in the Option Field, QLT will notify Novartis (the “Option
Notice”) of its intention to further develop and commercialize the use of Verteporfin in one or
more dermatological conditions in the specified Option Field. Upon Novartis’ request, QLT will
provide reasonably promptly to Novartis its views on the clinical and pre-clinical data possessed
by QLT related to the use of Verteporfin for the dermatological conditions that are the subject of
the Option Notice, along with QLT’s then current plans for the continued development and

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

37

 

commercialization of Verteporfin for those dermatological conditions and will reasonably
discuss the same with Novartis.

14.2.2 If Novartis wishes to participate in the commercialization of Verteporfin in the
dermatological conditions described in the Option Notice, Novartis will notify QLT of such intent
within thirty days after receipt of the Option Notice and QLT and Novartis will then negotiate each
in good faith the financial and all other material terms of an agreement pertaining to the
commercialization of Visudyne in such dermatological indications. If:

1. Novartis notifies QLT that it does not wish to participate in such
commercialization of Verteporfin;

2. Novartis fails to notify QLT that it wishes to participate in such
commercialization of Verteporfin in the time period set out above; or

3. Novartis and QLT fail to enter into a letter of intent with respect to
the commercialization of Verteporfin in the dermatological conditions
described in the Option Notice prior to the 60th day after the date of QLT’s
Option Notice or if Novartis and QLT fail to enter into a binding agreement
with respect to the commercialization of Verteporfin in the dermatological
conditions described in the Option Notice within 60 days thereafter;

then QLT will be free to pursue alone, or enter into agreements with one or more Third Parties for,
the promotion, distribution and/or sale of Verteporfin in the dermatological conditions that were
the subject of the Option Notice. Except where the events referred to in (1) and (2) above
occurred, for a period of one year following the date that QLT and Novartis discontinue such
negotiations such agreements with Third Parties will not be on terms and conditions that are
materially more favorable to the Third Party than those previously offered by QLT to Novartis.

14.2.3 Nothing in this Section 14 will obligate QLT to pursue the development, regulatory
approval or commercialization of Verteporfin for use in any dermatological condition.

	14.3	 	Right of First Option to Commercialize Verteporfin in Certain PDT Dermatology Fields After
the Transition Effective Date

Notwithstanding Section 14.1 and 14.2, upon and after the Transition Effective Date the right of
first option to commercialize Verteporfin in certain PDT Dermatology Fields pursuant to this
Section 14 shall be of no further force or effect.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

38

 

Section 15 Sharing of Development Expenses

	15.1	 	Parties to Fund their Share of the Cost of Development Programs

Each party shall fund its share of the cost of all Development Programs incurred in any fiscal year
calculated in accordance with the Funding Formula and paid in accordance with the mechanism set out
in this Section 15.

	15.2	 	Funding Formula for Development Expenses

Subject to Section 19.2, the formula for the funding of Development Expenses (the “Funding
Formula”) shall be as set out in this Section 15.2:

15.2.1 the Development Expenses for BPD will be split 60% to Novartis and 40% to QLT, except
for regulatory filing fees paid to a regulatory authority, which will be split 50% to Novartis and
50% to QLT;

15.2.2 the Development Expenses for ZnPc will be split 50% to Novartis and 50% to QLT and
regulatory fees paid to a regulatory authority will be split 50% to Novartis and 50% to QLT;

15.2.3 in respect of any Additional Photosensitizer, as determined in advance by the mutual
agreement of QLT and Novartis, acting reasonably.

	15.3	 	How Funding Obligations Met

The funding obligation of each party for all Development Expenses to be incurred in any fiscal year
shall be met in three ways, namely:

15.3.1 by each party performing (and being credited for) Labour on Development;

15.3.2 by each party contributing to (and being credited for such contributions) the payment
of Third Party costs in accordance with Section 16; and

15.3.3 in accordance with any Settlement Payment to be issued pursuant to Section 17.

	15.4	 	Limitation on Funding

Neither party shall recover from the other or be credited for any Development Expenses:

15.4.1 incurred on any activities in a Development Program for which the JCC has not approved
a budget for such activities; or

15.4.2 in excess of the amount contained in the budget for such Development Expenses without
the prior written approval of the JCC.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

39

 

	15.5	 	Inability to Meet Funding Obligations

The parties acknowledge that there may be circumstances whereby the JCC determines that certain
Work under a Development Program should be performed, but one party is unable to meet its funding
obligation under the Funding Formula. In such circumstances, either party may, at its option, fund
the entire costs of such additional Development (“Optional Research and Development”) and the party
which funds the full costs of such Optional Research and Development shall be entitled to such
compensation as the JCC determines is appropriate in the circumstances, acting reasonably.

	15.6	 	Development Expenses after the Transition Effective Date

Notwithstanding Section 15.1 through 15.5, upon and after the Transition Effective Date, for
clarity, the parties shall cease any Development, and accordingly the parties shall cease to share
Development Expenses incurred upon and after the Transition Effective Date in connection with all
Products, including but not limited to the Visudyne Product. There shall be a final reconciliation
of any Development Expenses accrued prior to the Transition Effective Date included in the overall
final profit share statement and final distribution of Net Sales of Visudyne Products before the
Transition Effective Date in accordance with Section 18.

Section 16 Payment under the Funding Formula

16.1 Payments under the Funding Formula

If a party has incurred less costs and expenses than its proportionate share of Development
Expenses, it shall remit to the other party an amount equal to the quotation set out in the Funding
Formula described in Section 15.2 of the difference between its costs and expenses to those of the
other party, such remittance being paid within a further sixty (60) days after the date of the
later of the two statements described in Section 17.5. Subject to and not inconsistent with the
Release provisions of Sections 26.1 to 26.4 inclusive, any dispute arising with respect to
Development activities conducted prior to the Transition Effective Date between the parties as to
what costs and expenses are to be shared as Development Expenses shall be referred to the JCC,
except that if such dispute arises after the Transition Effective Date, such dispute may be
referred first to the parties’ representatives provided for in Section 5.7.2, and if such
representatives fail to resolve such dispute within thirty (30) days, to arbitration by either
party for determination pursuant to Section 29.2. For clarity, this Section 16.1 shall not apply to
any development expenses incurred for Products after the Transition Effective Date.

Section 17 Settlement Payments

	17.1	 	Payment of Settlement Payments

The parties shall calculate and make Settlement Payments in accordance with the terms of this
Section 17 as to Development Expenses incurred for Product prior to the Transition Effective Date.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

40

 

	17.2	 	Creation of Reconciliation Statements

Within forty-five (45) days of the end of each Calendar Quarter, the Program Coordinator of each
Development Program shall provide to the JCC quarterly reconciliation statements in the form
established by the JCC for the funding status of each of the Development Programs in the Global
Development Plan.

	17.3	 	How Reconciliations Calculated

Reconciliations shall be calculated on the aggregate of the Development Programs undertaken so that
each party funds its full share of the Development Expenses of those programs and recovers any
Development Expenses incurred by it that are in excess of the amount that would have been borne by
it under the Funding Formula.

	17.4	 	Who Makes and Receives Settlement Payments

Settlement Payments shall be made to the party whose total Development Expenses exceed the
Development Expenses that should have been incurred by such party pursuant to the Funding Formula,
to the extent of such excess. Settlement Payments shall be made by the party whose total
Development Expenses falls short of the Development Expenses that should have been incurred by such
party pursuant to the Funding Formula, to the extent of such shortfall.

	17.5	 	Timing and Procedure of Settlement Payments

Settlement Payments of Development Expenses shall be made by both parties in accordance with the
quarterly reconciliation statements and according to the procedures established by the JCC.
Settlement Payments shall be made in Swiss currency and paid by wire transfer to the bank account
of each party of which the other party has been given notice from time to time. Settlement
Payments for Development Expenses shall be made:

17.5.1 annually, at a minimum; or

17.5.2 when a reconciliation statement indicates that a pre-set Reconciliation Threshold is
exceeded by any party.

	17.6	 	Determination of Reconciliation Thresholds

Each party shall establish its “Reconciliation Threshold” annually and notify the JCC of same. The
Reconciliation Threshold represents the total amount of Development Expenses a party is prepared to
incur without payment of a Settlement Payment to restore such party to the position it would have
been in had the parties each incurred no more than the proportion of the Development Expenses each
is obliged to incur pursuant to this Agreement. The JCC is responsible for initiating requests for
Settlement Payments when a party notifies the JCC that its Reconciliation Threshold has been
reached.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

41

 

Section 18 Proceeds from Net Sales

	18.1	 	Receipt and Distribution of Net Sales of Visudyne Products Prior to Transition Effective Date

Novartis will receive all Net Sales of Product occurring prior to the Transition Effective Date, in
trust for the benefit of the Alliance and distribute same forthwith after the end of each Calendar
Quarter in accordance with the terms of this Section 18.

	18.2	 	Deductions from Net Sales

Novartis shall deduct from Net Sales occurring prior to the Transition Effective Date:

18.2.1 the Marketing and Distribution Expenses attributable to such Net Sales and retain same
for its own benefit;

18.2.2 the Manufacturing Expenses attributable to such Net Sales and:

1. if Novartis is the manufacturer of the Product in respect of which the
Net Sales were received, retain same for its own benefit;

2. if QLT is the manufacturer of the Product in respect of which the Net
Sales were received, pay same to QLT;

18.2.3 any Third Party Royalties payable by either party in respect of the manufacture, use or
sale of the Product in respect of which such Net Sales were made, and, if QLT is the party obliged
to pay such royalties, pay same to QLT. For the avoidance of doubt, any ongoing liability on the
part of QLT to make payments to MEEI and MGH in respect of the litigation referred to at Section 26
shall not be deemed a Third Party Royalty for the purposes of the Agreement.

	18.3	 	Distribution of Remainder

The remainder of Net Sales occurring prior to the Transition Effective Date after deduction as
contemplated in Section 18.2 shall be credited to the parties and distributed in the proportions
contemplated in Section 19.

	18.4	 	Timing of Distributions

All payments and distributions to be made in accordance with this Section 18 shall be made by
Novartis to QLT concurrently with the distribution of the sales report contemplated in Section 9.6.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

42

 

	18.5	 	Currency and Method of Payments

All payments to be made in accordance with this Section 18 shall be made by Novartis to QLT in
currency of the United States by couriered cheque or wire transfer to the bank account of QLT of
which Novartis has been given notice from time to time.

	18.6	 	Conversion of Currency

Payments shall be computed and made in U.S. dollars under this Section 18 by first converting the
Net Sales and all related costs from the local currency into Swiss francs in accordance with
Novartis’ normal accounting practices and then into U.S. dollars or such other currency as QLT may
request calculated using the “noon wholesale buying rate” published in The Wall Street Journal on
the last business day of the Calendar Quarter for such Net Sales.

	18.7	 	Credit to Novartis for Deficiencies

If, in respect of any Net Sales of Products occurring prior to the Transition Effective Date the
Manufacturing Expenses, Third Party Royalties and the Marketing and Distribution Expenses exceed
the Net Sales to which such expenses are attributable, then Novartis shall be entitled to credit
the amount of such deficiency that would be allocated to QLT in accordance with Section 19 against
future distributions to QLT to be made in accordance with Section 18.3.

	18.8	 	Proceeds From Net Sales After the Transition Effective Date

The parties shall no longer share any proceeds from Net Sales of the Product made upon and after
the Transition Effective Date pursuant to this Section 18. Instead, Novartis shall pay to QLT the
amounts due to it pursuant to Article 20, and QLT shall pay any applicable amounts due to Novartis
pursuant to Section 27.7.1.

Section 19 Calculation of Net Proceeds

	19.1	 	Proceeds Sharing

The underlying principle of this Agreement is that QLT and Novartis will equally share risks and
benefits through Development and commercialization of Products prior to the Transition Effective
Date as sole collaborators. Except as expressly otherwise set out in this Agreement to contemplate
credits for allocation of certain expenses as agreed between the parties as set out in Section 15.2
or modifications to the division of expenses and the benefit of such expenses as set out in Section
19.2, after deductions or credits for the Manufacturing Expenses, Third Party Royalties and the
Marketing and Distribution Expenses, the remainder (“Net Proceeds”) will be divided equally between
QLT and Novartis.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

43

 

	19.2	 	Modification to Division of Proceeds

If either party wishes to reduce its contribution to Development Expenses below the levels in
Section 15.2, and the other party agrees, this reduction will be reflected in a comparable
adjustment of the sharing of Net Proceeds as agreed to between the parties herein.

	19.3	 	Determination of Division of Proceeds

The determination of the Net Proceeds shall be made by both parties on a commercially reasonable
basis consistent with the terms of this Agreement. Both parties shall agree to use all reasonable
efforts to arrive at an equitable determination.

	19.4	 	Disputes as to Proceeds

Subject to and not inconsistent with the Release provisions of Section 26.1 to 26.4 inclusive, in
the event that the parties cannot agree on the determination of proceeds from Net Sales as provided
for in Section 19.1, either party may refer the matter for determination to arbitration in
accordance with Section 29.2. For the avoidance of doubt, any disagreement shall in no event relate
to matters released pursuant to Sections 26.1 to 26.4 inclusive.

	19.5	 	Calculation of Net Proceeds During the Pre-Transition Period and After the Transition
Effective Date

19.5.1 During the Pre-Transition Period, Sections 18 and 19 continue to apply and each of the
parties agrees that it will continue to include in Manufacturing Expenses, Third Party Royalties
and the Marketing and Distribution Expenses for Products only such costs and expenses as are
reasonable for the purposes of calculating Net Proceeds under this Agreement, consistent with past
practice. Each party agrees not to include in Manufacturing Expenses, Third Party Royalties and
the Marketing and Distribution Expenses for Products during the Pre-Transition Period any unusual
or exceptional costs or expenses without the prior written consent of the other party.

19.5.2 Upon and after the Transition Effective Date, Novartis shall book all sales in the
Novartis Territory and pay to QLT the royalties provided in Article 20, and Sections 18 and 19.1 to
19.4 (inclusive) shall no longer apply to sales in respect of orders placed after the Transition
Effective Date.

19.5.3 Upon and after the Transition Effective Date, QLT shall book all sales in the QLT
Territory. The JCC shall coordinate a transition to QLT of all orders received by Novartis prior to
the Transition Effective Date for Visudyne Product to be delivered after the Transition Effective
Date in the United States so that QLT thereafter can assume responsibility for fulfilling such
orders and distributing such Visudyne Product in the QLT Territory as required therefor, with QLT
booking all such sales.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

44

 

Section 20 Royalty Payments after Transition Effective Date for Visudyne Products

	20.1	 	Royalties

20.1.1 As partial consideration for the rights granted to Novartis under this Agreement, upon
and after the Transition Effective Date, Novartis shall no longer be obligated to make payments to
QLT pursuant to Sections 18 and 19 with respect to any Product, including but not limited to the
Visudyne Product, but shall pay to QLT a royalty of (i) twenty percent (20%) of Net Sales of the
Visudyne Product in the Novartis Territory by Novartis, its Affiliates and sublicensees occurring
during the period commencing on the Transition Effective Date until and including December 31,
2014, and (ii) sixteen percent (16%) of Net Sales of the Visudyne Product in the Novartis Territory
by Novartis, its Affiliates and sublicensees occurring during the period commencing on January 1,
2015 until and including December 31, 2019.

	20.2	 	Royalty Reports and Royalty Payment

20.2.1
Novartis will provide to QLT no later than [*] days after the end of each
Calendar Quarter (or portion thereof if this Agreement terminates during a Calendar Quarter)
following the Transition Effective Date, a full and accurate accounting of the following
information for each country in the Novartis Territory in which Net Sales of the Visudyne Product
were made by Novartis, its Affiliate and sublicensees during such Calendar Quarter:

1. the Net Sales for the Visudyne Product by Novartis, its Affiliates and
sublicensees in the currency in which sales were made and in U.S. dollars
after the application of the exchange rate during the reporting period, and
the calculations made in determining such Net Sales;

2. the royalties payable in United States dollars that have accrued
hereunder in respect of such Net Sales and the basis for calculating those
royalties; and

3. number of units of Visudyne Product sold in each country of the Novartis
Territory by Novartis, its Affiliates and sublicensees.

After the receipt of the royalty report for each Calendar Quarter (or portion thereof if this
Agreement terminates during a Calendar Quarter), QLT shall submit to Novartis an invoice in respect
of the royalty payment due for such Calendar Quarter (or portion thereof if this Agreement
terminates during a Calendar Quarter) in the form mutually agreed
upon by the parties within [*] days after the Restatement Date. Subject to Novartis’ approval of the invoice, Novartis shall
pay any such royalty payment due within [*] days of receipt of such invoice. All
payments under this Agreement shall be payable in US dollars. When conversion of payments from any
foreign currency is required to be undertaken by Novartis, the USD equivalent shall be calculated
using Novartis’ then-current standard exchange rate methodology as applied in its external
reporting.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

45

 

	20.3	 	Third Party Royalties after Transition Effective Date for Visudyne Products

20.3.1 Novartis shall reimburse to QLT all Third Party Royalties that are due and payable
pursuant to the UBC Agreement and the MGH Agreement on Net Sales of the Visudyne Product by
Novartis, its Affiliates or sublicensees in the Novartis Territory occurring upon and after the
Transition Effective Date through [*] subject to the following: (a) Novartis’ obligation to
reimburse royalties due pursuant to the MGH Agreement shall not [*]; and (b) Novartis’ obligation to reimburse
royalties due pursuant to the UBC Agreement shall not [*]. [*] shall pay all Third Party Royalties
that are [*] upon and after the Transition Effective Date, and except as provided in (a) and (b) of
the first sentence of this Section 20.3.1, [*]. Other than the foregoing Third Party Royalties and
subject to the provisions of Section 26 and Section 27.2.6, [*] shall be responsible for paying any
royalties or similar payments due to Third Parties with respect to the Net Sales of the Visudyne
Product in the [*], and [*] shall be responsible for paying any royalties or similar payments due
to Third Parties with respect to Net Sales of the Visudyne Product [*]. In the event that [*]
reasonably determines that rights to intellectual property owned or Controlled by a Third Party are
required to fully exercise the licenses to the [*] shall notify [*] of its desire to obtain such
license. In such case, the parties shall discuss in good faith [*] view of why such intellectual
property rights are required for such purpose and the material terms of compensation that [*]
expects to be necessary to obtain such license. [*] such license is [*], [*] the payments [*] of
the [*] by [*] to such Third Party. QLT shall not enter into any agreements with Third Parties that
would [*] with respect to [*] following the Restatement Date without [*].

20.3.2 Taxes and Withholding

In the event that any royalties or other payments due to QLT are subject to withholding tax
required by Applicable Law to be paid by Novartis to the taxing authority of any foreign country on
QLT’s behalf, Novartis may deduct the amount of such tax from the applicable royalties or other
payment otherwise payable to QLT. In such event, Novartis shall pay the taxes to the proper taxing
authority and shall send evidence of the obligation together with proof of payment to QLT following
such payment; provided, however, that prior to making any such withholding payment, Novartis shall
give QLT reasonable notice of its intention to withhold and the basis for such withholding, and
shall (both prior to and after any such withholding) reasonably cooperate with QLT in its efforts
to eliminate or minimize such withholding obligations and/or to obtain credit for payment thereof.

20.3.3 Records Retention after Transition Effective Date

Upon and after the Transition Effective Date, Novartis and its Affiliates will maintain (and will
ensure that Novartis’ permitted sublicensees and agents will maintain) complete and accurate books,
records and accounts that fairly reflect their respective gross sales, expenses, relevant
deductions from gross sales, Net Sales, calculations of transfer prices and costs in sufficient
detail to confirm the accuracy of any payments required or royalty reports made pursuant to this
Section 20 and in accordance with International Financial Reporting Standards (“IFRS”), which

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

46

 

books, records and accounts will be retained by Novartis for [*] after the end of the period to
which such books, records and accounts pertain.

	20.4	 	Financial Audit Rights, Reconciliation Payments; Confidentiality

20.4.1 After the Transition Effective Date, QLT will have the right to have an independent
accounting firm of internationally recognized standing, reasonably acceptable to Novartis, to have
access during normal business hours, and upon reasonable prior written notice, to such of the
records of Novartis and its Affiliates as may be reasonably necessary to verify the accuracy of any
royalty reports made pursuant to Section 20.2 including the accuracy of gross sales, applicable
deductions from gross sales, and Net Sales for any Calendar Quarter ending not more than [*] prior
to the date of such request; provided, however, that QLT will have the right to conduct no more
than one (1) such audit in each country in the Novartis Territory in any twelve (12) month period
and not more frequently than once with respect to records covering any specific period of time.
The accounting firm will provide QLT and Novartis with a written report of its findings. QLT will
bear the cost of such audit.

20.4.2 If, based on the results of such audit, additional payments are owed by Novartis under
this Agreement, Novartis will promptly make such additional payments. Novartis will include such
additional payments, together with interest on such additional payments at an annual rate of [*] in
the next quarterly royalty report due at the latest. If the audit finds that Novartis has paid
more to QLT than it was obligated to pay under this Agreement, QLT will reimburse Novartis for such
overpayment and will pay to Novartis interest on such overpayment at an annual rate of [*]. The
provisions of this Section 20.4.2 shall also apply to any errors discovered by either party in the
quarterly royalty report which have led to an overpayment or underpayment of royalties.

20.4.3 QLT will treat all information subject to review under this Article 20 in accordance
with the confidentiality provisions of Article 24 and will cause its accounting firm to enter into
a reasonably acceptable confidentiality agreement with Novartis obligating such firm to maintain
all such financial information in confidence pursuant to such confidentiality agreement.

Section 21 Relationship of the Parties and Accounting

	21.1	 	Alliance Relationship

The association of the parties is strictly limited to the purpose described in this Agreement and
will not be extended, by implication or otherwise. It is not the purpose of this Agreement or the
intention of the parties to create, nor will this Agreement be construed to create, a partnership
or in any way to render the parties liable as partners.

	21.2	 	Authorized Expenditures

Except to the extent provided by this Agreement, no party will have the authority to incur any
costs or expenses on behalf of the Alliance, or to assume any obligation, liability or

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

47

 

responsibility on behalf of the other party, or engage any other individual, firm or corporation to
perform any portion of the Work or provide any services or material for the Alliance.

	21.3	 	Accounting

For the administrative convenience of the parties, the JCC will cause the interests of the parties
in the Assets, the parties’ obligations for the Development Expenses, and the contributions of each
party to be recorded on a common set of books and accounts kept in accordance with accounting
principles to be determined by the JCC and on the basis of a December 31 year-end, separately from
the recording of the other business transactions carried on by either patty.

	21.4	 	Financial Reports

On or before the tenth Business Day of each succeeding month, each Program Coordinator, under the
supervision of the JCC, will have prepared from such accounts and provided to the JCC:

21.4.1 a schedule of Assets for the Alliance as at the end of the previous month, with
comparison to budget;

21.4.2 a statement of Development Expenses for the previous month, with comparison to budget;

21.4.3 a statement of the interests of each party in the Alliance, including the amounts each
party was entitled to payment, with comparison to budget;

21.4.4 such other information as is material to the operations of the Alliance; and

21.4.5 such other information relating to the operation of the Alliance as either party
reasonably requests;

showing the several interests of the parties therein.

	21.5	 	Books of Account and Records

Each party shall keep proper books of account and records and supporting vouchers respecting all
matters under this Agreement and shall allow the other party by its duly appointed representative
or accountant at its own costs and at all reasonable times upon reasonable notice to inspect and
take copies of or extracts from such books, records, vouchers for the purpose of verifying the
amounts under this Agreement.

	21.6	 	The Parties Relationship and Accounting After the Transition Effective Date

21.6.1 During the Pre-Transition Period Sections 21.3 through 21.5 shall apply with respect
to activities relating to any Product, including but not limited to the Visudyne Product, occurring
prior to the Transition Effective Date.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

48

 

21.6.2 Upon and after the Transition Effective Date Sections 21.3 through 21.5 shall no longer
apply with respect to activities relating to any Product, including but not limited to the Visudyne
Product, occurring on or after the Transition Effective Date.

Section 22 Representations and Warranties

	22.1	 	Representations of Each Party

Each party makes the representations and warranties to the other party as set out in this
Section 22.

	22.2	 	Title to Products

Each party hereby represents and warrants to the other that it has good and marketable title to,
and the right to sell, its Products including such licensing of technology and patent rights as are
useful and necessary for the parties to carry out the terms of this Agreement.

	22.3	 	Representations and Warranties of Novartis

Novartis hereby represents and warrants as follows:

22.3.1 Novartis has been duly incorporated and organized and is validly subsisting and in good
standing in its jurisdiction of incorporation. Novartis has the corporate power to own or lease
its property and to carry on the business as now being conducted by it;

22.3.2 the entering into of this Agreement and the transactions contemplated hereby shall not
result in the violation of any of the terms and provisions of the constating documents of Novartis
or of any indenture or other agreement, written or oral, to which Novartis may be a party;

22.3.3 the entering into of this Agreement and the transactions contemplated hereby shall not
result in the violation of any law or regulation of any country;

	22.4	 	Representations and Warranties of QLT

QLT hereby represents and warrants as follows:

22.4.1 QLT has been duly incorporated and organized and is validly subsisting and in good
standing with the Registrar of Companies (British Columbia); it has the corporate power to own or
lease its property and to carry on the business as now being conducted by it;

22.4.2 the entering into of this Agreement and the transactions contemplated hereby shall not
result in the violation of any of the terms and provisions of the constating documents of QLT or of
any indenture or other agreement, written or oral, to which QLT may be a party;

22.4.3 the entering into of this Agreement and the transactions contemplated hereby shall not
result in the violation of any law or regulation of any country; and

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

49

 

22.4.4 to QLT’s knowledge, the entering into of this Agreement is in accordance with [*] and
will not [*] prior to the Restatement Date.

Section 23 Limitations On Liability And Indemnity

	23.1	 	SPECIFIC EXCLUSION OF OTHER WARRANTIES

EXCEPT AS EXPRESSLY SET OUT IN THIS AGREEMENT, EACH PARTY MAKES TO THE OTHER NO WARRANTIES,
REPRESENTATIONS, CONDITIONS, OR GUARANTEES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED BY LAW
OR CUSTOM.

	23.2	 	LIMITED DAMAGES

IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY IN CONTRACT OR IN TORT FOR DAMAGES FOR
LOST PROFITS, LOST SAVINGS, OR INCIDENTAL, INDIRECT, CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES IN
CONNECTION WITH THE SALE OR USE OF THE PRODUCTS OR ANY PART THEREOF OR THIS AGREEMENT UNLESS CAUSED
BY SUCH PARTY’S WILFUL MISCONDUCT.

	23.3	 	MONETARY LIMIT

IF, DESPITE THE FOREGOING LIMITATIONS, FOR ANY REASON EITHER PARTY BECOMES LIABLE TO THE OTHER
PARTY FOR DAMAGES INCURRED IN CONNECTION WITH THE MANUFACTURE, DELIVERY, IMPORTATION, SALE OR USE
OF THE PRODUCTS OR ANY PART THEREOF OR THIS AGREEMENT, THEN, THE AGGREGATE LIABILITY OF SUCH PARTY
FOR ALL DAMAGES, INJURY, AND LIABILITY INCURRED BY THE OTHER PARTY AND ALL THIRD PARTIES IN
CONNECTION WITH PRODUCTS SHALL BE LIMITED TO AN AMOUNT EQUAL TO SUCH PARTY’S THEN ACCUMULATED SHARE
OF NET SALES CALCULATED IN ACCORDANCE WITH SECTION 18. IF THIS AMOUNT IS NOT ENOUGH TO COVER THE
AGGREGATE LIABILITY OF SUCH PARTY, THEN THE LIABILITY AMOUNT SHALL BE DEDUCTED FROM THE FUTURE
SHARE OF NET SALES PROCEEDS OF SUCH PARTY AT THE RATE OF 50% OF SUCH PARTY’S DISTRIBUTION PAYMENTS
UNTIL THE LIABILITY IS COVERED.

	23.4	 	INDEMNITY ONLY REMEDY FOR INFRINGEMENT

EACH PARTY’S ONLY RIGHTS AND REMEDIES IN CONNECTION WITH CLAIMS BY THIRD PARTIES THAT ANY PRODUCTS,
THE RIGHTS LICENSED UNDER THIS AGREEMENT, OR THE EXPLOITATION THEREOF INFRINGES THE INTELLECTUAL
PROPERTY OR PROPRIETARY RIGHTS OR TRADE SECRETS OF SUCH CLAIMANTS SHALL BE LIMITED TO THE INDEMNITY
SET OUT IN SECTIONS 23.5 AND 23.6.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

50

 

	23.5	 	Novartis Indemnity

Novartis agrees to indemnify and save harmless QLT from and against all claims, actions, direct
damages, losses, costs and expenses of any kind (including that arising out of physical injury)
made upon QLT by any third party:

23.5.1 respecting the manufacture, transport or storage of ZnPc and any Additional
Photosensitizers for which Novartis is the Drug Owner and the sale, distribution or use of any
Products, except for those for which QLT indemnifies Novartis pursuant to Section 23.6; and

23.5.2 that the rights licensed by Novartis to QLT under this Agreement, or the exploitation
thereof infringes its lawful property rights, including rights in any valid patent, copyright, or
trade secret.

	23.6	 	QLT Indemnity

QLT agrees to indemnify and save harmless Novartis from and against all claims, actions, direct
damages, losses, costs and expenses of any kind (including that arising out of physical injury made
upon Novartis by any third party:

23.6.1 respecting the manufacture, transport, storage and sale to Novartis of BPD (except to
the extent arising from activities conducted with respect to the Visudyne Product after the
Transition Effective Date) or any Additional Photosensitizer for which QLT is the Drug Owner;

23.6.2 respecting any promotional activities for the Visudyne Product in North America by QLT
or a Third Party acting on QLT’s behalf (other than Novartis) prior to the Transition Effective
Date; and

23.6.3 that the rights licensed by QLT to Novartis under this Agreement, or the exploitation
thereof infringes its lawful property rights, including rights in any valid patent, copyright, or
trade secret.

	23.7	 	Limitation of Liability and Indemnity After the Transition Effective Date

Sections 23.1, 23.2, 23.4 shall govern the parties’ limitations on liability and indemnity with
respect to activities conducted regarding the Product prior to the Transition Effective Date.

Sections 23.1, 23.2, 23.4 shall continue to govern the parties’ limitations on liability and
indemnity with respect to activities conducted regarding the Visudyne Product upon and after the
Transition Effective Date, except that in Section 23.4 the reference to Section 23.5 and 23.6 shall
be deemed to refer instead to Sections 23.7.1 and 23.7.2, and Section 23.3 shall cease to apply
solely with regard to activities conducted upon or after the Transition Effective Date in respect
of the Visudyne Product.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

51

 

23.7.1 Novartis shall indemnify and save harmless QLT and its Affiliates from and against all
claims, actions, direct damages, losses, costs and expenses of any kind (including that arising out
of physical injury) made upon QLT and/or an Affiliate by any third party:

1. respecting the sale, distribution or use of the Visudyne Product by
Novartis, its Affiliate or sublicensee in the Novartis Territory on and
after the Transition Effective Date, except for those for which QLT
indemnifies Novartis pursuant to Section 23.7.2, and the limitation at
Section 23.2 shall not apply to this Section 23.7.1; or

2. arising from Novartis’ material breach of this Agreement, or its
negligence or recklessness on or after the Transition Effective Date.

23.7.2 QLT shall indemnify and save harmless Novartis and its Affiliates from and against all
claims, actions, direct damages, losses, costs and expenses of any kind (including that arising out
of physical injury) made upon Novartis and/or an Affiliate by any third party:

1. respecting the manufacture, transport, storage and sale to Novartis of
Visudyne Product on and after the Transition Effective Date, but excluding
any claims respecting the manufacture of the Visudyne Product by Novartis or
its Affiliates or Third Party independent contractors engaged by Novartis to
the extent permitted under this Agreement;

2. respecting the sale, distribution or use of the Visudyne Product by QLT,
its Affiliate or sublicensee in the QLT Territory on and after the
Transition Effective Date, including the content of the Web Site it provides
in the course of exercising its obligations under Section 10.11.9 after the
Transition Effective Date, except for those for which Novartis indemnifies
QLT pursuant to Section 23.7.1, and the limitation at Section 23.2 shall not
apply to this Section 23.7.2; or

3. arising from QLT’s material breach of this Agreement or its negligence or
recklessness on or after the Transition Effective Date.

	23.8	 	Limitation on Indemnities

The indemnities set out in Sections 23.5, 23.6, 23.7.1 and 23.7.2 shall apply only on the condition
that:

23.8.1 the indemnifying party shall have sole conduct of all proceedings and negotiations
connected with such claims;

23.8.2 the other party shall promptly notify the indemnifying party of all such claims and
shall not make any admissions regarding them;

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

52

 

23.8.3 the amount of this indemnity shall not in the aggregate exceed the limit set out in
Section 23.3 in respect of the indemnities in Sections 23.5 and 23.6;

23.8.4 the other party shall provide the indemnifying party with reasonable assistance and
authority in connection with such claims; and

23.8.5 if a claim is alleged as contemplated by Sections 23.5.2 or 23.6.2, or the indemnifying
party reasonably believes that a claim shall be alleged then, at its own expense, the indemnifying
party may procure for the other party a license to continue to using the infringing item, and/or
the indemnifying party may modify or replace the infringing item to avoid infringement.

Section 24 Proprietary Information

	24.1	 	Obligation of Confidentiality

Novartis and QLT agree that it is in the best interest of both parties if the exchange of
Proprietary Information is limited to that required for performance under this Agreement. Neither
party shall communicate the other party’s Proprietary Information to any Third Party and each party
shall use its best efforts to prevent inadvertent disclosure of the other party’s Proprietary
Information to any third party.

	24.2	 	Identification of Proprietary Information

A recipient of Proprietary Information shall be obligated to protect such Proprietary Information
disclosed under this Agreement as is:

24.2.1 disclosed in tangible form clearly labelled as confidential at the time of disclosure;
or

24.2.2 disclosed initially in non-tangible form identified as confidential at the time of
disclosure and, within thirty days following the initial disclosure, summarized and designated as
confidential in a written memorandum delivered to the recipient.

	24.3	 	Property in Proprietary Information

All Proprietary Information received under this Agreement shall be the sole and exclusive property
of the disclosing party absolutely, whether or not the Proprietary Information is capable of
patent, copyright, registered design or like protection, and whether or not such protection has
been or is sought or taken out.

	24.4	 	Acknowledgement of Confidentiality

Each of the parties acknowledge and confirm that any and all identified Proprietary Information
either party has received from the other prior to and since the Effective Date was obtained, at the
time of its receipt, under an obligation of confidentiality on the terms as set forth herein.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

53

 

	24.5	 	Duration of Obligation

The confidentiality obligations under this Agreement shall extend for five years from receipt of
the Proprietary Information or the expiry or earlier termination of this Agreement, whichever
occurs later.

	24.6	 	Exclusions from Proprietary Information

This Agreement imposes no obligation on the receiving party with respect to Proprietary Information
disclosed under this Agreement if the receiving party can conclusively demonstrate that the
information:

24.6.1 was in the receiving party’s possession before receipt from the disclosing party; or

24.6.2 is or becomes a matter of public knowledge through no fault of the receiving party; or

24.6.3 is rightfully received by the receiving party without a duty of confidentiality; or

24.6.4 is disclosed by the disclosing party to a third party without a duty of confidentiality
of the third party; or

24.6.5 is disclosed under the operation of law or the requirement of a government agency; or

24.6.6 is disclosed by the receiving party with the prior written approval of the disclosing
party; or

24.6.7 is independently developed by the receiving party.

	24.7	 	Disclosure to Consultants

Novartis and QLT may utilize the services of third party consultants from time to time in
connection with a Development Program or otherwise exercising their rights to develop the Visudyne
Product upon and after the Transition Effective Date. The parties agree that Proprietary
Information of either of them may be disclosed to such consultants provided that the party making
the disclosure:

24.7.1 requires the consultant to sign a confidentiality agreement setting forth the
consultant’s obligations with respect to Proprietary Information, which shall be consistent with
this Section 24; and

24.7.2 limits the disclosure to the information necessary to enable the consultant to provide
the consulting services.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

54

 

	24.8	 	Disclosure to Employees

Novartis and QLT shall ensure that all of their respective employees who may receive Proprietary
Information of the other party have signed an agreement setting forth the employee’s obligations
with respect to Proprietary Information in accordance with the party’s normal employment practices.

Section 25 Proprietary Rights

	25.1	 	Patent Listing

As of the Restatement Date:

25.1.1 QLT Patents are listed in the attached Schedule 1.1.64;

25.1.2 Joint Patents, Novartis [*] Patents and Novartis Patents are listed in the attached
Schedules 1.1.29, 1.142 and 1.1.44, respectively.

	25.2	 	Update of Listing

Schedule 1.1.64 shall be updated from time to time or at the request of Novartis by QLT to include
new QLT Patents and forthwith provided to Novartis. Schedule 1.1.44 shall be updated from time to
time or at the request of QLT by Novartis to include new Novartis Patents and forthwith provided to
QLT.

	25.3	 	Further Information Regarding Patents

QLT, in respect of QLT Patents, and Novartis, in respect of Novartis Patents, shall each, at the
request of the other, provide copies of any patent files and histories. The recipient of such
information agrees to treat it as the disclosing party’s Proprietary Information pursuant to the
terms of this Agreement.

	25.4	 	Ownership of Proprietary Rights

Except as expressly provided in this Agreement, each party agrees that it shall have or obtain no
rights in the other party’s proprietary rights, products, materials and methodologies except
pursuant to a separate written agreement executed by the parties.

	25.5	 	Ownership of Work Product in General

Until the Transition Effective Date, any inventions, discoveries, improvements, ideas, concepts,
know-how and techniques developed pursuant to a Development Program by either party or jointly by
the parties’ personnel, and any Novartis Patents, QLT Patents, or Joint Patents, shall be treated
as follows:

25.5.1 if made solely in respect of BPD, they shall be the property of QLT and QLT shall grant
to Novartis an exclusive and royalty-free licence in the Field to use same to the extent

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

55

 

necessary and solely for the purposes of developing, manufacturing and distributing Products,
all as contemplated by this Agreement; and

25.5.2 if made solely in respect of ZnPc, they shall be the property of Novartis and Novartis
shall grant to QLT an exclusive and royalty-free licence in the Field to use same to the extent
necessary and solely for the purposes of developing, manufacturing and distributing Products, all
as contemplated by this Agreement; and

25.5.3 if the circumstances set out in Section 25.5.1 and 25.5.2 do not apply:

1. if made by an employee, agent or licensee of QLT, they shall be the
property of QLT and QLT shall grant to Novartis an exclusive and
royalty-free licence in the Field to use same to the extent necessary and
solely for the purposes of developing, manufacturing and distributing
Products, all as contemplated by this Agreement;

2. if made by an employee, agent or licensee of Novartis, they shall be the
property of Novartis and Novartis shall grant to QLT an exclusive and
royalty-free licence in the Field to use same to the extent necessary and
solely for the purposes of developing, manufacturing and distributing
Products, all as contemplated by this Agreement; and

3. if jointly made by employees, agents or licensees of both QLT and
Novartis, they shall be jointly owned by QLT and Novartis without any
accounting for it and QLT and Novartis shall each have the right to use,
license and otherwise exploit same without the further consent of the other
party but subject to the terms of this Agreement.

25.5.4 Notwithstanding anything to the contrary set forth in Sections 25.5.1 through 25.5.3,
ownership of inventions, discoveries, improvements, ideas, concepts, know-how and techniques
developed or made by the parties’ personnel, solely or jointly, pursuant to this Agreement after
the Transition Effective Date in respect of [*].

	25.6	 	Registrations

25.6.1 With respect to any proprietary rights owned by either party, the party owning such
proprietary rights may file such patent or other applications in such countries as such party shall
deem advisable. Each party will provide the other with information with respect to registration of
proprietary rights through the updating of their respective schedules for QLT Patents or Novartis
Patents, as appropriate.

25.6.2 From the Transition Effective Date onward, Novartis may file any patent applications
claiming [*] that are made upon or after the Transition Effective Date in respect of [*]; provided
that such patent applications and patents shall be [*]. From the Transition Effective Date onward,
QLT may file any patent applications claiming [*] that are made upon or

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

56

 

after the Transition Effective Date [*]; provided that such patent applications and patents
shall be [*].

	25.7	 	Prosecution of Patents

The owner of each patent will pay for and have control over the applications for their respective
patents. Novartis and QLT shall jointly own all Joint Patents [*] and shall employ mutually
acceptable counsel for the purpose of timely preparing, filing, prosecuting, and maintaining such
Patents. The expenses associated with Joint Patents and other jointly owned Patents shall be
shared equally by QLT and Novartis. Assessments of rights and determinations regarding the
registration of Joint Patents and other jointly owned Patents shall be made by the JCC.

	25.8	 	Notice Requirement

25.8.1 After the Effective Date, a party asserting sole ownership to any work product
developed pursuant to a Development Program shall provide reasonable notice to the other party of
its intention to seek patent protection of such proprietary rights. The other party shall have a
reasonable opportunity to review and comment on such assertions prior to the filing of a patent
application.

25.8.2 Notwithstanding the foregoing, if after the Transition Effective Date one party desires
to file for patent protection of any Visudyne Inventions that are solely owned by such party
(subject to Section 25.6), such party may proceed independently with respect thereto with no
obligation to provide notice to the other party pursuant to Section 25.8.1.

	25.9	 	Mandatory License

The parties shall grant to each other a non-exclusive license to use and exploit the intellectual
property owned or controlled by the licensing party created pursuant to any Development Program,
solely for the purposes of performing under this Agreement, which license continues on termination
or expiration of this Agreement to the extent necessary for a party to exercise its rights after
termination as provided in Section 27.

	25.10	 	Patent Prosecution After the Transition Effective Date

25.10.1 If, after the Transition Effective Date, Novartis elects not to continue to prosecute
and thereby abandon a Patent claiming any of its intellectual property rights included in the
Novartis Technology relating to the Visudyne Product or (subject to pre-existing rights granted to
Third Parties as of the Restatement Date) the Novartis [*] Patents, in either case in the QLT
Territory, or elects not to maintain and thereby abandon any such Patent, it will notify QLT not
less than [*] before any relevant deadline, and offer to assign all right, title and interest in
such Patent to QLT. If QLT chooses to obtain all right, title and interest in and to such Patent
from Novartis, QLT will thereafter have the right, but not the obligation, to pursue, at QLT’s
expense and in QLT’s sole discretion, prosecution and maintenance of such Patent thereafter. If,
after the Transition Effective Date, QLT elects not to continue to prosecute and thereby abandon a
Patent claiming any of its intellectual property rights included in the QLT
Technology relating

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

57

 

to the Visudyne Product in the Novartis Territory, or elects not to
maintain and thereby abandon any such Patent, it will notify Novartis not less than [*] before any
relevant deadline, and offer to assign all right, title and interest in such Patent to Novartis,
subject to Section 25.10.2 below. If Novartis chooses to obtain all right, title and interest in
and to such Patent from QLT, subject to Section 25.10.2 below, Novartis will thereafter have the
right, but not the obligation, to pursue, at Novartis’ expense and in Novartis’ sole discretion,
prosecution and maintenance of such Patent thereafter, provided that if Novartis elects not to
continue to prosecute and thereby abandon such Patent claiming any of its intellectual property
rights included in the QLT Technology relating to the Visudyne Product in the Novartis Territory,
or elects not to maintain and thereby abandon any such Patent, it will notify QLT not less than [*]
before any relevant deadline to enable QLT to [*], and otherwise cooperate to assist QLT in
connection with its obligations under such agreement.

25.10.2 Notwithstanding Section 25.10.1, if QLT elects not to prosecute or maintain any Patent
claiming any of its intellectual property rights included in the QLT Technology relating to the
Visudyne Product in the Novartis Territory, and Novartis desires to obtain all right, title and
interest in and to such Patent pursuant to Section 25,10.1, but [*], QLT shall grant to Novartis an
exclusive (even as to QLT), royalty bearing, perpetual sublicense under such [*] QLT Technology, to
research, develop, make, have made, use, import, offer for sale and sell the Visudyne Product in
the Novartis Territory upon and after the Transition Effective Date, subject to Section 10.11.6.
Such sublicense shall be subject to any limitations imposed under [*], and shall be limited to the
scope of the rights granted to QLT [*]. In the event QLT grants to Novartis the license set forth
in this subsection 25.10.2 above, QLT shall cooperate with Novartis to pursue, at Novartis’ expense
and in Novartis’ sole discretion, the preparation, filing, prosecution, and maintenance of such
Patent thereafter.

Section 26 Release — Potential Disputes

	26.1	 	Mutual Release

Each party on behalf of itself and its heirs, successors, assigns, administrators, executors,
agents and representatives, hereby expressly releases, remits, acquits and forever discharges the
other party, its predecessors, subsidiaries, successors, Affiliates, former Affiliates, and each of
their current and former officers, directors, shareholders, employees, managers, principals,
affiliates, representatives, assignees, attorneys, insurers, predecessors-in-interest,
successors-in-interest, customers, manufacturers, vendors, suppliers, distributors, and agents
(collectively, the “Releasees”) from any and all manner of action or actions, cause or causes of
action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability,
claims, demands, damages, charges, losses, costs, or legal costs (including all attorneys’ fees or
expenses), of any nature whatsoever known or unknown, fixed or contingent, choate or inchoate,
existing up to or relating to the period up to and including the Restatement Date (collectively,
the “Claims”), [*].

	26.2	 	MEEI Litigation

26.2.1 QLT, on behalf of itself and its heirs, successors, assigns, administrators, executors,
agents and representatives, hereby expressly releases, remits, acquits and forever

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

58

 

discharges Novartis, its predecessors, subsidiaries, successors, Affiliates, former
Affiliates, and each of their current and former officers, directors, shareholders, employees,
managers, principals, affiliates, representatives, assignees, attorneys, insurers,
predecessors-in-interest, successors-in-interest, customers, manufacturers, vendors, suppliers,
distributors, and agents (collectively, the “Novartis Releasees”) from any and all Claims which QLT
now has against the Novartis Releasees relating or connected to, or arising out of costs and
liabilities incurred by QLT in conducting the litigation between QLT Phototherapeutics Inc. and
Massachusetts Eye and Ear Infirmary (“MEEI”) in connection with events related to U.S. patent No.
5,798,349 and certain of MEEI’s research results related to the Visudyne Product; provided that [*]
in connection with the litigation involving MEEI. Subject to the foregoing, any payments that
become or are payable to MEEI in connection with sales of the Visudyne Product anywhere in the
world shall be paid by QLT. This release applies and extends to all rights, causes of action, or
Claims asserted, or which could have been asserted, by QLT as of the Restatement Date with respect
to the costs incurred by QLT in connection with the litigation involving MEEI, irrespective of the
theory of recovery that could have been asserted.

26.2.2 Novartis, on behalf of itself and its heirs, successors, assigns, administrators,
executors, agents and representatives, hereby expressly releases, remits, acquits and forever
discharges QLT, its predecessors, subsidiaries, successors, Affiliates, former Affiliates, and each
of their current and former officers, directors, shareholders, employees, managers, principals,
affiliates, representatives, assignees, attorneys, insurers, predecessors-in-interest,
successors-in-interest, customers, manufacturers, vendors, suppliers, distributors, and agents
(collectively, the “QLT Releasees”) from any and all Claims, which Novartis now has against the QLT
Releasees relating or connected to, or arising out of the costs and liabilities incurred by
Novartis in conducting the litigation involving MEEI. This release applies and extends to all
rights, causes of action, or claims asserted, or which could have been asserted, by Novartis as of
the Restatement Date, irrespective of the theory of recovery that could have been asserted.

	26.3	 	MGH Litigation

QLT, on behalf of itself and its heirs, successors, assigns, administrators, executors, agents and
representatives, hereby expressly releases, remits, acquits and forever discharges the Novartis
Releasees from any and all Claims, which QLT now has or may hereafter have against the Novartis
Releasees relating or connected to, or arising out of damages alleged by MGH in the litigation
involving MGH, [*]. This release applies and extends to all rights, causes of action, or claims
asserted, or which could have been asserted, by QLT as of the Restatement Date, irrespective of the
theory of recovery that could have been asserted.

	26.4	 	[*] Obligations

QLT, on behalf of itself and its heirs, successors, assigns, administrators, executors, agents and
representatives, hereby expressly releases, remits, acquits and forever discharges Novartis
Releasees from any and all Claims which QLT now or may hereafter have against Novartis’ Releasees
relating or connected to, or arising out of [*] prior to the Transition Effective Date, [*].

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the
Securities and Exchange Commission. Confidential treatment has been requested with respect to
the omitted portions.

 

59

 

Section 27 Term and Termination

	27.1	 	Term

This Agreement shall come into force and effect from the Restatement Date, and shall, unless sooner
terminated according to Section 27.3 hereto, remain in full force and effect until December 31,
2019.

	27.2	 	Expiration of Term

Upon the expiration of the term or any renewal thereof (“Expiration Date”), the following will
apply, except as otherwise expressly set out in this Agreement:

1. the parties shall be liable for all payment obligations accrued prior to
the Expiration Date;

2. the parties shall return to each other within two (2) months of the
Expiration Date all tangible Proprietary Information with respect to
Products other than the Visudyne Product disclosed to them by the other;

3. except as expressly set forth in Subsection 27.2.6 below, neither party
shall have any rights to the intellectual property of the other, including
the Novartis Patents, the Novartis [*] Patents, the QLT Patents and the QLT
[*] Patents;

4. Novartis shall forthwith pay to QLT royalties on Net Sales of the
Visudyne Product, calculated in accordance with this Agreement for all Net
Sales made up to the Expiration Date;

5. the parties shall continue to be bound by confidentiality obligations
pursuant to Article 24 with respect to tangible Proprietary Information
disclosed to them with respect to Visudyne Products by the other for so long
as they continue to commercialize Visudyne Products and for five (5) years
thereafter;

6. each party will retain their rights to the Visudyne Product in the
relevant territory as set forth in Section 8 of this Agreement (i.e.
Sections 8.1 and 8.2 shall survive such expiration) on a royalty-free,
fully-paid basis, provided that (i) [*] for Third Party Royalties due and
payable to [*] and the [*] due to MEEI with respect to Net Sales of the
Visudyne Product in the Novartis Territory following such expiration (such
[*] not to exceed three and one hundredth of one percent (3.01%) of Net
Sales of the Visudyne Product in the Novartis Territory), and (ii) except as
set forth in Subsection (i), each party will be responsible for Third Party
Royalties due with respect to Net Sales of the Visudyne Product in such
party’s territory

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

60

 

following expiration of this Agreement, provided for the avoidance of doubt
that this shall not include any [*]; and

7. Novartis will comply with the material obligations imposed by the UBC
Agreement and MGH Agreement to the extent that they apply to activities
conducted by Novartis at such time pursuant to this Agreement after the term
of this Agreement.

	27.3	 	Early Termination

27.3.1 Novartis shall have right to terminate this Agreement for convenience as to the
Visudyne Product in its entirety or on country-by-country basis by giving to QLT twelve (12) months
prior written notice.

27.3.2 This Agreement shall terminate prior to the expiration of the term or any renewal
thereof upon the occurrence of any one of the following events: if prior to the Transition
Effective Date, either party breaches this Agreement or fails to make any payment to the other
party required hereunder when due (either one being an “Event of Default”) and such Event of
Default remains unremedied for sixty (60) consecutive days after notice thereof is given to the
party in breach or failing to make such payment, and the other party then gives notice in writing
of termination, which will be effective upon receipt.

27.3.3 If during the term of this Agreement Novartis, its Affiliates and sublicensees Cease to
Commercialize the Visudyne Product in a country in the Novartis Territory, then QLT shall have the
right to send a notice to Novartis, in which case the parties shall meet to discuss in good faith a
resolution. If Novartis decides that it does not wish to continue to commercialize in such country
or if the parties fail to agree on a resolution within thirty (30) days after Novartis receives
QLT’s notice, Novartis shall be deemed to have terminated this Agreement with respect to such
country under Section 27.3.1, provided that in such case the twelve (12) month notice period set
forth in Section 27.3.1 shall not apply.

	27.4	 	General Effect of Early Termination

Termination of this Agreement, in whole or in part, before the expiration of the term or any
renewal thereof, shall be without prejudice to the right of any party accrued to the effective date
of such termination, without prejudice to the remedies of either party in respect to any previous
breach of any of the representations, warranties or covenants herein contained and without
prejudice to any rights to indemnification set forth herein and to any other provisions hereof
which expressly or necessarily call for performance after such termination. In addition to and
without limiting the generality of the foregoing, except as otherwise expressly set out in Section
27.5, upon early termination of the term of this Agreement by either party, Sections 27.4.1 and
27.4.2 shall apply:

27.4.1 the parties shall return to each other within two (2) months of termination all
tangible Proprietary Information disclosed to them by the other, except to the extent necessary for
a party to exercise its rights after such termination as provided in this Section 27; and

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

61

 

27.4.2 neither party shall have any rights to the intellectual property of the other,
including the Novartis Patents, the Novartis [*] Patents, the QLT Patents and the QLT [*] Patents,
except to the extent necessary for a party to exercise its rights after such termination as
provided in this Section 27.

	27.5	 	Effect of Termination Due to An Event of Default

27.5.1 If the Agreement is terminated as a result of an Event of Default by either party:

1. if such termination is effective prior to the Transition Effective Date,
the parties shall be liable for their respective shares of all Development
Expenses incurred up to the effective date of such termination in addition
to any other liabilities arising up to the date of such termination;

2. if such termination is effective prior to the Transition Effective Date,
the parties shall jointly and forthwith prepare a reconciliation of the
sharing of Development Expenses to the date of termination, and, where
appropriate, make any Settlement Payment resulting therefrom, except that if
Novartis is required to make a Settlement Payment to QLT, it may withhold
the amount of such Settlement Payment, if any, that relates to any other
payment which QLT has failed to make to Novartis under this Agreement;

3. if such termination is effective prior to the Transition Effective Date,
each party’s rights to share in the Net Sales shall cease as of the
effective date of termination, but Novartis shall forthwith pay to QLT its
share of Net Sales, calculated in accordance with this Agreement for all Net
Sales made up to the effective date of termination, except that if such
Event of Default was by QLT, Novartis may withhold the amount of any such
payment due to QLT that relates to any other payment which QLT has failed to
make to Novartis under this Agreement;

4. if such termination is effective prior to the Transition Effective Date,
the mandatory licenses granted by each party to the other pursuant to the
provisions of Section 25.9 shall be terminated;

5. Novartis’ and QLT’s licenses under Section 8.1 and 8.2 shall survive such
termination, subject to the payment obligations set forth in Section 20; and

6. if requested by Novartis, QLT shall continue to manufacture or have
manufactured and sell to Novartis the Visudyne Product for a price equal to
the price set forth in Section 9.6.3, and the other provisions of Section 9
shall apply, mutatis mutandis.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

62

 

	27.6	 	Effect of Termination for Convenience

If the Agreement is terminated by Novartis for convenience with respect to Visudyne Products in
accordance with Section 27.3.1, the following shall apply to the Visudyne Product:

1. The parties may continue to exercise the rights and shall perform their
obligations under the Agreement up to the effective date of termination, and
shall be liable for all costs, expenses and payments for which they are
responsible under this Agreement that accrue during the notice period.

2. Novartis’ license under Section 8.2 shall terminate effective as of such
termination date as to the country(ies) as to which Novartis has terminated
the Agreement, and Section 27.7.1 shall apply to such country(ies).

	27.7	 	Rights to Visudyne Product in the Other’s Territory After Certain Terminations

27.7.1 In the event during the term of this Agreement Novartis terminates or is deemed to have
terminated this Agreement or its rights to the Visudyne Product in whole or in part pursuant to
Sections 27.3.1 or 27.3.3, as applicable, QLT shall have the exclusive right to develop, make, have
made, use, sell, offer for sale and import the Visudyne Product in all such terminated countries,
[*]. If QLT elects to obtain such rights to the Visudyne Product in such country, the country or
countries as to which such termination applies shall be deemed to be included in the QLT Territory
for purposes of the licenses set forth in Section 8, except that QLT shall thereafter pay Novartis
a royalty on Net Sales of the Visudyne Product in such country or countries [*], calculated mutatis
mutandis pursuant to Article 20 as if such sales were by Novartis, its Affiliates or sublicensees
in such country.

27.7.2 In the event during the term of this Agreement QLT, its Affiliates and sublicensees,
Cease to Commercialize Visudyne Products in the QLT Territory pursuant to Section 10.11.10,
Novartis shall have the right to send a notice to QLT, in which case the parties shall meet to
discuss in good faith a resolution. If QLT decides that it does not wish to continue to
commercialize in the QLT Territory the Visudyne Product, or if the parties fail to agree on a
resolution within thirty (30) days after QLT receives Novartis’ notice, QLT shall be deemed to have
terminated this Agreement with respect to its rights to the Visudyne Product in the QLT Territory.
Thereafter, Novartis shall have the exclusive right to develop, make, have made, use, sell, offer
for sale and import the Visudyne Product in the QLT Territory (subject to QLT’s rights under
Article 9 and the MSA) [*]. If Novartis elects to obtain such rights to the Visudyne Product in the
QLT Territory, the QLT Territory shall be deemed to be included in the Novartis Territory for
purposes of the licenses set forth in Section 8, [*].

Section 28 Rights in Bankruptcy

28.1 All licenses granted under or pursuant to this Agreement, are, and will otherwise be deemed to
be, for the purposes of Section 365(n) of the US Bankruptcy Code (the “Code”) and

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

63

 

any similar laws in the Territory, license of rights to “intellectual property” as defined under
Section 101 of the Code. The parties agree that each party will retain and may fully exercise all
or its protections, rights and elections under the Code and any similar laws in any other country
in each party’s Territory, and nothing in this Agreement is intended to nullify, supercede or
derogate from any protections available to either party under any applicable bankruptcy or
insolvency law, including Section 365(n) of the Code and any similar laws in any other country in
each party’s Territory. The parties further agree that, in the event of the commencement of a
bankruptcy proceeding by or against one party under the Code and any similar laws in any other
country in either party’s Territory, the other party will be entitled to a complete duplicate of
(or complete access to, as appropriate) any such intellectual property and all embodiments of such
intellectual property, and the same, if not already in its possession, will be promptly delivered
to it (i) upon any such commencement of a bankruptcy proceeding upon its written request therefore,
unless such party (or its bankruptcy estate) elects to continue to perform all of its obligations
under this Agreement, or (ii) if not delivered under (i) above, following rejection of the
Agreement by or on behalf of such party upon written request therefore by the other party.

28.2 All rights, powers and remedies of the parties provided for in this Section 28 are in addition
to and not in substitution for any and all other rights, powers and remedies now or hereafter
existing at law or in equity (including, without limitation, under the Code and any similar laws in
any other country in each party’s Territory). In the event of the bankruptcy of one party, the
other party, in addition to the rights, power and remedies expressly provided herein shall be
entitled to exercise all such other rights and powers and resort to all other such remedies as may
now or hereafter exist at law or in equity (including, without limitation, under the Code). The
parties agree that they intend the following rights to extend to the maximum extent permitted by
law (including, without limitation, for the purposes of the Code: (i) the right of access to any
intellectual property (including embodiments thereof) of the other party, or any Third Party, to
the extent a party is able to provide such rights at such time, with whom such party contracts to
perform and obligation of such party under this Agreement which is necessary for the development,
registration, manufacture and/or commercialization of the Visudyne Product in the Novartis
Territory; (ii) the right to contract directly with any Third Part described in (i) to complete the
contracted work and (iii) the right to cure any breach of or default under any such agreement with
a Third Party and set off the costs thereof against amounts payable to a party under this
Agreement).

Section 29 General

	29.1	 	Amendment

No modification, supplement or amendment to this Agreement shall be binding unless executed in
writing by both parties.

	29.2	 	Arbitration

Except for applications for injunctions for the protection of Proprietary Information, in any claim
pertaining to a controversy, dispute or matter arising out of or relating to this Agreement
(including any matter that may be referred to arbitration for a determination hereunder), the party

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

64

 

asserting such claim shall first inform the other parties, in writing, of the specific nature of
the controversy, dispute or matter, the pertinent provisions of this Agreement, and its proposed
resolution. The parties shall attempt to resolve the claim through good faith negotiations for a
period of thirty (30) days, unless the asserting party is suffering irreparable harm, in which case
appropriate further action may be taken immediately. If such efforts are not successful, the claim
shall be submitted to arbitration in accordance with the Commercial Arbitration Rules of the
American Arbitration Association by a panel of three arbitrators knowledgeable as to the subject
matter of the claim, and judgment upon the award rendered by the Arbitrator(s) may be entered in
any court having jurisdiction thereof. The arbitrators shall have the right to order discovery as
they deem appropriate, and to order injunctive relief and the payment of attorney’s fees, costs,
and other damages herein excluding punitive damages. Any arbitration conducted hereunder shall
take place in New York.

	29.3	 	Assignment

29.3.1 Except as herein provided (including without limitation in Section 8.1), QLT may not
assign, transfer, subcontract or sublicense in whole or in part any of its rights or obligations
hereunder without the written consent of Novartis, such consent not to be unreasonably withheld;
provided however, that, without Novartis’ prior consent, QLT may assign its rights and obligations
hereunder to an Affiliate, or to a Third Party that is the successor to the whole of its business
in PDT or with respect to the Visudyne Product, provided that QLT shall not be relieved of its
obligations hereunder. Novartis may assign or transfer, in whole or in part of any of its rights
or obligations hereunder to an Affiliate or to a Third Party that succeeds to the whole of its
business with respect to the Visudyne Product, provided that Novartis shall not be relieved of its
obligations hereunder without the written consent of QLT.

29.3.2 To the extent any assignment in whole, but not in part, by Novartis of its rights or
obligations hereunder to a person or entity outside Switzerland (the “Entire Assignment”) would
result in adverse withholding tax consequences to QLT, Novartis shall pay QLT a Gross-Up Amount at
the time such withholding is made. For purposes of this Section 29.3, “Gross-Up Amount” shall mean
such additional amounts sufficient to put QLT in the position it would have occupied but for such
transfer or exercise of such rights or obligations, limited to the amount of withholding pursuant
to the applicable reduced withholding tax rate provided for in the applicable income tax treaty, if
any, between Canada and the jurisdiction of the party exercising Novartis’ rights or subject to
Novartis’ obligations, provided that the benefits of such treaty are available. Notwithstanding
the foregoing, (i) QLT shall refund to Novartis the amount by which the withholding tax giving rise
to the Gross-Up Amount was a Creditable Amount (as defined below) in the tax year in which the
relevant royalty or other payment is included in QLT’s income for tax purposes; (ii) in furtherance
of clause (i), after the filing of QLT’s Canadian corporate tax return for the tax year in which
the relevant royalty or other payment is included in QLT’s income for Canadian corporate tax
purposes, an officer of QLT shall deliver to Novartis a written certification representing to
Novartis whether and to what extent the taxes withheld from such royalties or other payments to QLT
hereunder in such tax year were utilizable by QLT as a credit against Canadian corporate taxes paid
or payable by QLT for such tax year and the extent to which they were not so utilizable (the
“Creditable Amount” and the “Uncreditable

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

65

 

Amount”, respectively), together with supporting information reasonably necessary to permit
the confirmation thereof; and (iii) if QLT (or any assignee of QLT) is not, or has ceased to be,
resident for tax purposes in Canada, and no withholding would have been required were QLT (or such
assignee) resident for tax purposes in Canada, then no Gross-Up Amount shall be required to be
paid.

29.3.3 To the extent (a) any subcontract or sublicense in whole or in part or any other
transfer (other than an Entire Assignment) by Novartis (or any of its Affiliates) of any of its
rights or obligations hereunder to a person or entity outside Switzerland, or (b) the exercise of
the license pursuant to Section 8.2.1 or 8.2.2 by any Affiliate of Novartis, would result in
adverse withholding tax consequences to QLT, Novartis shall pay QLT a Gross-Up Amount at the time
such withholding is made; provided, however, that if QLT (or any assignee of QLT) is not, or has
ceased to be, resident for tax purposes in Canada, and no withholding would have been required were
QLT (or such assignee) resident for tax purposes in Canada, then no Gross-Up Amount shall be
required to be paid.

29.3.4 Notice of any assignment shall be given by the party making the assignment to the other
party within thirty (30) days of the date thereof. Any attempted assignment contrary to the
provisions of this Section 29.3 shall be void.

	29.4	 	Counterparts; Facsimile

This Agreement may be executed by the parties in any number of counterparts with the same effect as
if both parties had signed the same document. All counterparts shall be construed together and
shall constitute one and the same agreement. This Agreement may be executed by the parties and
transmitted by facsimile transmission and if so executed and transmitted this Agreement shall be
for all purposes as effective as if the parties had delivered an executed original Agreement.

	29.5	 	Drafting

Each party to this Agreement has cooperated in the drafting and preparation of this Agreement.
Thus, in any construction to be made of this Agreement, the same shall not be construed against any
party.

	29.6	 	Entire Agreement

This Agreement, including all Exhibits and Schedules hereto, represents the entire agreement and
understanding between the parties and supersedes all previous representations, warranties,
dealings, negotiations and discussions, agreements, understandings and expectations of the parties,
whether oral or written, regarding the subject matter hereof, and there are no other
representations, warranties, understandings, conditions, agreements, or expectations between the
parties regarding the subject matter hereof except as set out herein.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

66

 

	29.7	 	Enurement

This Agreement shall enure to the benefit of and be binding upon the parties and their respective
successors and permitted assigns.

	29.8	 	Force Majeure

The obligations of each party hereto shall be suspended during such time and to the extent that
fulfilment of any such obligation shall be prevented or delayed by circumstances beyond the control
of the party affected thereby which that party could not have avoided by the exercise of reasonable
diligence. The party so affected shall: (a) notify the other party promptly of the occurrence or
likely occurrence of such circumstances, and the likely period during which the performance of its
obligations hereunder will be prevented or delayed thereby; and (b) resume performance of its
obligations as soon as practicable. If such reasons for delay or default continuously exist for
six (6) months, this Agreement may be terminated upon thirty (30) days notice by either party.

	29.9	 	Headings

The headings in this Agreement form no part of this Agreement and shall be deemed to have been
inserted for general information and reference only, and this Agreement shall not be construed by
reference to such headings.

	29.10	 	Law; Courts

This Agreement shall be construed, and the rights of the parties determined, in accordance with the
laws of the State of New York of the United States. The venue of any legal proceedings to resolve
any dispute between the parties shall be Zurich if QLT is the plaintiff and Vancouver if Novartis
is the plaintiff.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

67

 

	29.11	 	Non-Competition

Subject to Section 13, while this Agreement is in effect, neither Novartis or those Affiliates of
Novartis listed in Schedule 29.11 (collectively “Novartis Affiliates”) nor QLT or its Affiliates
will, within the Territory, either directly or indirectly, sell or assist any other person to sell
the Visudyne Products in the Field, except as expressly permitted under this Agreement. For
greater certainty, but not so as to limit the generality of the foregoing, neither Novartis or the
Novartis Affiliates nor QLT or its Affiliates will knowingly assist any individual, corporation,
trust, group, or other entity or association that carries on any of such restricted activities
above in conducting such activities, whether as a shareholder, lender or otherwise, or through a
chain of individuals, corporations, trusts, entities, or associations.

	29.12	 	Notice

Unless otherwise specified herein, any notice or other communication required or permitted to be
given under this Agreement may be delivered personally or be sent by prepaid registered post
addressed to the party addressed as follows:

	 	 	 
	If to QLT:	 	If to Novartis:
	 
	 
	QLT Inc.

	 	Novartis Pharma AG
	887 Great Northern Way, Suite 101

	 	Postfach
	Vancouver, British Columbia, Canada

	 	CH-4002 Basel
	V5T 4T5

	 	Switzerland
	 
	 	 
	Attention: President and Chief Executive
Officer

	 	Attention: Head, Business
Development and Licensing
	 
	 	 
	with a copy to:
	 	 
	 
	 	 
	QLT Inc.

	 	Novartis Pharma AG
	887 Great Northern Way, Suite 101

	 	Lichtstrasse 35
	Vancouver, British Columbia, Canada

	 	Basel, Ch-4002
	V5T 4T5

	 	 
	 
	 	Attention: General Counsel, Legal Department
	Attention: Chief Legal Officer

	 	
	 
	 	 
	And
	 	 
	 
	 	 
	Latham & Watkins LLP
	 	 
	140 Scott Drive
	 	 
	Menlo Park, CA 94025
	 	 
	Attention: Alan Mendelson, Esq.
	 	 

and any such notice or other communication shall be deemed to have been given to the party to whom
it was addressed and received by that party on delivery, if delivered personally, and on the

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

68

 

third business day following the mailing thereof, if mailed. Either party may change the address
to which notice is to be given as provided herein.

	29.13	 	Publicity

Neither party shall make any public announcement concerning this Agreement or referring to a party
without the prior written approval by the other party with regard to the form, content and precise
timing of such announcement, except as may be required by either party with respect to compliance
with any Applicable Law. Such consent shall not be unreasonably withheld or delayed by the other
party. Prior to any public announcement concerning this Agreement or referring to a party, the
party wishing to make the announcement will submit a draft of the proposed announcement to the
other party in sufficient time (a minimum of 5 days where reasonably possible) to enable the other
party to consider and comment thereon. If the parties are unable to agree on the form or content
of any such required disclosure, and such disclosure is required by Applicable Law, such disclosure
shall be limited to the minimum required as determined by the disclosing party in consultation with
its legal counsel.

	29.14	 	Publications

While it is understood that both Novartis and QLT shall be free to publish the results of their
respective studies carried out under this Agreement, until the Transition Effective Date, both QLT
and Novartis agree to provide the other the opportunity to review any proposed abstracts, posters
and other material or information to be published or presented at a scientific meeting, and any
manuscripts at least thirty (30) days prior to their intended presentation or submission for
publication and, at either party’s request, shall delay presentation or submission for a period
sufficient to permit adequate steps to be taken to secure patent protection for any patentable
subject matter referred to therein. The reviewing party shall carry out its review with reasonable
promptness and approval for publication shall not be unreasonably withheld. QLT and Novartis will
delay or refrain from publication if either party can demonstrate this to be contrary to its
commercial interests or damaging to the project contemplated by this Agreement. Upon and after the
Transition Effective Date, each party shall continue to be free to publish the results of their
respective studies carried out under this Agreement, however both QLT and Novartis agree to provide
the other with prior notification of such results within fifteen (15) days of being accepted to be
presented or accepted for publication.

	29.15	 	Severability

If any one or more provisions of this Agreement is invalid, illegal or found to be unenforceable
(by a court from which there is no appeal, or no appeal is taken in any jurisdiction) for any
reason whatsoever, the validity, legality or enforceability of such provision or provisions shall
not in any way be affected or impaired thereby in any other jurisdiction, and the unenforceability
shall not affect the validity, legality or enforceability of the remaining provisions of the
Agreement, and the unenforceable, illegal or invalid provision or provisions shall be severable
from the remainder of this Agreement, provided that this severance does not alter the basic
structure of this Agreement. In such event, the parties shall renegotiate this Agreement in good
faith, but should such negotiations not result in a new agreement within ninety (90) days of the

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

69

 

initiation of such negotiations, then this Agreement may be terminated by either party by thirty
(30) days written notice to the other party.

	29.16	 	Sharing of Information

Until the Transition Effective Date, each party will make available and disclose to each other all
information known by either party concerning the Field as of the Effective Date and at any time
thereafter through the JCC. All discoveries or inventions made by either party in the Field will
be promptly disclosed to the other. The parties, through the Project Teams, will exchange verbal
or written reports not less often than once per Calendar Quarter presenting a meaningful summary of
their respective Work done under this Agreement. Each party will make regular presentations to the
other of its Work through the JCC, and additionally as reasonably requested by the other party, and
will communicate informally and through the JCC to inform the other party of Work done under this
Agreement. Each party will use its best reasonable efforts not to communicate information to the
other which has no application to the Field. Each party will provide the other with raw data in
original form or a photocopy thereof for any and all Work carried out in the course of the
Development as reasonably requested by the other Party. This Section 29.16 shall not apply upon and
after the Transition Effective Date.

	29.17	 	Survival

The provisions of Sections 1 (Definitions), 8.1 (Licenses to QLT), to the extent provided in
Section 27, 8.2 (Licenses to Novartis), to the extent provided in Section 27, 9 (to the extent
applicable under Section 27), 10.11.9 (Website), 11 (Regulatory Approvals, to the extent the
parties retain rights to commercialize the Visudyne Product after the term), 12.4 (Trademarks for
Product after the Transition Effective Date, to the extent relevant to the parties’ activities
after the Transition Effective Date), 15.6 (Development Expenses after the Transition Effective
Date, to the extent necessary to effect any applicable reconciliation), 16.1 (Payments under the
Funding Formula, to the extent necessary to resolve cost sharing prior to the termination), 17
(Settlement Payments, to the extent necessary to effect settlements of payments during the term),
18 (Proceeds from Net Sales, to the extent necessary to effect the sharing of net Sales during the
term), 19 (Calculation of Net Proceeds, to the extent necessary to effect the sharing of risks and
benefits prior to the termination as provided therein), 20 (Royalty Payments after the Transition
Effective Date, to the extent necessary to effect payments for activities conducted during the term
or, to the extent provided in Section 27, thereafter), 21.5 (Books of Account and Records, subject
to Section 21.6), 23 (Limitations on Liability and Indemnity), 24 (Proprietary Information, for so
long as provided therein, subject to extension pursuant to Section 27), 25 (Proprietary Rights), 26
(Releases), 27 (Term and Termination), 28 (Rights in Bankruptcy) and 29 (General), shall survive
any expiry or earlier termination of this Agreement.

	29.18	 	Waiver

A waiver of any breach of any provision of this Agreement shall not be construed as a continuing
waiver of other breaches of the same or other provisions of this Agreement.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

70

 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement in duplicate, each copy being
deemed an original effective as of the Effective Date.

	 	 	 	 	 	 	 
	QLT Inc.	 	 	 	 
	 
	 	 	 	 	 	 
	By:
	 	/s/ Robert L. Butchofsky 	 	 
	 	 	 	 	 
	 

	 	Name:	 	Robert L. Butchofsky 	 	 
	 

	 	Title:	 	President and Chief Executive Officer 	 	 
	 
	 	 	 	 	 	 
	Novartis Pharma AG	 	 
	 
	 	 	 	 	 	 
	By:
	 	/s/ Sarah Clements 	 
	 	 	 	 	 
	 

	 	Name:	 	Sarah Clements 	 	 
	 

	 	Title:
	 	Senior Legal
Counsel	 	 
	 
	 	 	 	 	 	 
	By:
	 	/s/ Knut Sturmhoefel 	 
	 	 	 	 	 
	 

	 	Name:	 	Knut Sturmhoefel 	 	 
	 

	 	Title:
	 	Head Alliance Management BF NSO	 	 

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

71

 

EXHIBIT A

VERTEPORFIN

The finished drug product is a lyophilized dark green cake. Verteporfin is a 1:1 mixture of
two regioisomers (I and II), represented by the following structures:

The
chemical names for the verteporfin regioisomers are:

9-methyl
(I) and 13-methyl
(II) trans-(+)-18-ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,
25H-benzo[b]porphine-9,13-dipropanoate

The molecular formula is C41H42N4O8 with
a molecular weight of approximately 718.8.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

72

 

Schedule 1.1.29: Joint Patents

[*]

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

73

 

Schedule 1.1.42: Novartis [*] Patents

[*]

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

74

 

Schedule 1.1.44: Novartis Patents

[*]

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

75

 

Schedule 1.1.64: QLT Patents

[*]

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

76

 

Schedule 1.1.81 Visudyne Trademark

US trademark registration nr. 2498651 VISUDYNE

	 	 	 
	Filing date: June 30, 1998

	 	Filing nr. 76/507102
	 
	 	 
	Registration date: October 16, 2001

	 	Registration nr. 2498651
	 
	 	 
	Next renewal date: October 16, 2001
	 
	 	 
	Registered Owner: Novartis AG, 4002 Basel, Switzerland

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

77

 

Schedule 5.4: JCC Authorities and Rules of Procedure

	1	 	Attendance

Every appointee of the Joint Coordinating Committee is entitled to receive notice of and to
attend and be heard at every meeting of the JCC, and, subject to Section 11 of this
Schedule, to vote thereat.

	2	 	Quorum

A quorum of the JCC shall consist of four appointees of whom two are appointed by each
party, neither of whom is disqualified pursuant to Section 11 of this Schedule.

	3	 	Regular Meetings

The JCC shall meet regularly and not less than four times each year at a location as the JCC
may from time to time determine.

	4	 	Special Meetings

In addition to regular meetings, the JCC shall meet as circumstances may require at the call
of the Chairperson of the JCC. Any appointee of the JCC may also requisition a meeting of
the JCC by requiring the Secretary to call the same. Special meetings shall be held at a
location determined by consensus of the JCC (whether formally or informally obtained), or,
failing such consensus, at the location of the previous meeting of the JCC. The JCC may at
any special meeting dispense with the holding of the next ensuing regular meeting.

	5	 	Notice

The Secretary shall furnish each appointee with at least forty-eight hours’ notice of each
special meeting of the JCC. Notices shall be in writing and shall set forth those matters
which the Chairperson of the JCC instructs or the requisitioning appointees instruct the
Secretary are expected or desired to be dealt with at the meeting to which they relate.
Notices shall be either delivered personally or transmitted by facsimile transmission
addressed to each appointee at the facsimile number given by the appointee to the Secretary.
Notice of an adjourned meeting of the JCC is not required to be given if the time and place
thereof is announced at the original meeting. Notice of any meeting of the JCC may at any
time be waived by any appointee.

	6	 	Meetings by Communications Facilities

A meeting of the JCC may be held where one or more of all appointees participate by means of
such communications facilities as permit all persons participating in the meeting to hear
each other, and any appointee so participating shall be deemed to have been present at that
meeting.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

78

 

	7	 	Consent Resolutions

A resolution consented to in writing by all such appointees of the Joint Coordinating
Committee signing the resolution or a counterpart thereof or indicating each appointee’s
consent by facsimile transmission or other means of delivering a written message, will have
the same force and effect as a motion passed unanimously at a meeting of the JCC duly called
and constituted, held on the date specified in the resolution or, if no date is so
specified, on the date of consent by the last appointee.

	8	 	Procedure

Subject to Section 10 of this Schedule, all matters to be dealt with by the JCC shall be
decided by resolution of a duly constituted meeting of the JCC only. The Chairperson of any
meeting shall determine any question of procedure, order, or privilege arising at such
meeting as the Chairperson may see fit, but in so deciding the Chairperson shall conform to
generally accepted rules of order.

	9	 	Outsiders

No persons other than appointees of the JCC shall be entitled to be admitted to any meeting
of the JCC without the unanimous consent of the meeting.

	10	 	Special Committees

In addition to the JCC’s rights to constitute Project Teams as set out in the Agreement, the
JCC may from time to time create one or more sub-committees to consider and make
recommendations to the JCC on such matters as the JCC may specify.

	11	 	Interests of Appointees

An appointee who is party to any contract or proposed contract with the Alliance or has a
material interest in any person, firm or corporation that is a party to any contract or
proposed contract with the Alliance shall forthwith on becoming so interested disclose in
writing to the JCC or request to have entered in the minutes of the meetings of the JCC the
nature and extent of the appointee’s interest, and shall refrain from any discussion or
voting thereon; provided, however, that this section shall not apply to any
interest that may arise solely through the fact that an appointee is a director, officer or
shareholder of a party that appointed the appointee to the JCC or any Affiliate thereof.

	12	 	Powers and Duties of Appointees

12.1 All appointees shall sign such contracts, documents or instruments in writing as require their
respective signatures and shall respectively have and perform all powers and duties incident to
their respective offices and such other powers and duties respectively as may from time to time be
assigned to them by the JCC.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

79

 

12.2 Contracts, documents or instruments in writing requiring the signature of the Alliance may be
signed on behalf of the Alliance by:

	(i)	 	the Chairperson and the Vice-Chairperson of the JCC; or

	 	(iii)	 	any two appointees of the JCC, of whom one is appointed by QLT and one by
Novartis;

and all contracts, documents and instruments in writing so signed shall be binding upon the
parties to the Alliance without any further authorization or formality. In addition, the
JCC may by resolution appoint any appointee or other person or persons on behalf of the
Alliance either to sign any class of contracts, documents or instruments in writing or to
sign a specific contract, document or instrument in writing.

	13	 	Financial Year

The financial year of the Alliance shall terminate on the 31st day of December in each
calendar year.

	14	 	PDT Product Development, Manufacturing and Distribution Agreement

In the event of any inconsistency between this Schedule and the Alliance Agreement to which
it is appended, the PDT Product Development, Manufacturing and Distribution Agreement shall
prevail.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

80

 

Schedule 10.1: Novartis Distributorship Countries as at the Effective Date

	 	 	 
	COUNTRY	 	DISTRIBUTOR
	 
	 	 
	Europe
	 	 
	 
	 
	AUSTRIA

	 	Gebro Broschek GmbH
	BENELUX

	 	CIBA Vision
	CYPRUS

	 	Vamavas Hadopanayis Ltd.
	DENMARK

	 	CIBA Vision
	FINLAND

	 	Leiras OY
	FRANCE

	 	CIBA Vision
	GERMANY

	 	CIBA Vision
	GREECE

	 	Savvas Th. Theodorides
	ICELAND

	 	Stefan Thoranensen Ltd.
	IRELAND

	 	United Drug _LC
	ITALY

	 	CIBA Vision
	LUXEMBOURG

	 	Prophac Zim_eld & Cie.
	MALTA

	 	Class Company Ltd.
	NETHERLANDS

	 	CIBA Vision
	NORWAY

	 	CIBA Vision
	PORTUGAL

	 	CIBA Vision
	NORWAY

	 	CIBA Vision
	SWEDEN

	 	Leiras OY
	SWITZERLAND

	 	CIBA Vision
	SPAIN

	 	CIBA Vision
	TURKEY

	 	CIBA Vision
	UNITED KINGDOM

	 	CIBA Vision
	 
	 	 
	N. America
	 	 
	 
	 
	USA

	 	CIBA Vision
	CANADA

	 	CIBA Vision
	 
	 	 
	S. America
	 	 
	 
	 
	ARGENTINA

	 	CIBA Vision
	BOLIVIA

	 	Schmidts Pharma S.R.L.
	CHILE

	 	Ciba Geigy Ltda.
	COLUMBIA

	 	Ciba Geigy S.A.
	DOM REPUBLIC

	 	Ocus C. por. A. Carretera de Herrera
	ECUADOR

	 	Giby Geigy S.A.
	EL SALVADOR

	 	Grimaldi S.A. de C.V.
	GUATEMALA

	 	Farmacia y D_ogueria Washington
	HONDURAS

	 	Corporation Parmaceutica S. De R.L. de C.V.
	JAMAICA

	 	Cari Med Ltd.
	MEXICO

	 	Ciba Geigy
	PANAMA

	 	Medimex S.A.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

81

 

	 	 	 
	COUNTRY	 	DISTRIBUTOR
	 
	 	 
	PARAGUAY

	 	Comfar S.R._
	PERU

	 	Distribuidora Albis S.A.
	TRINIDAD

	 	Agostini’s Ltd.
	URUGUAY

	 	Ciba Geigy
	VENEZUELA

	 	Ciba Geigy
	 
	 	 
	Eastern Europe
	 	 
	 
	 
	BULGARIA

	 	Ciba Geigy A/G
	CZECH REPUBLIC

	 	Gehe Pharm
 _____ 
r.o.
	HUNGRY

	 	Ciba Geigy, Hungaropharma, Medimpex, Pharmafrontara
	POLAND

	 	Pharm Supply Ltd., Orfe Sp.z.o.o.
	ROMANIA

	 	Optimed SR_
	SLOVAC REPUBLIC

	 	Martimex Komplet Corp.
	SLOWENIA

	 	Irman D.O.O.
	 
	 	 
	Middle East
	 	 
	 
	 
	EGYPT

	 	Orchidia Promotion
	BAHRAIN

	 	Awal Pharmacy
	IRAQ

	 	Gen. Establ. Marketing of Drgs + Med. Appl
	ISRAEL

	 	M. Jabosohn Ltd.
	JORDAN

	 	Nabih Nabuls Drugstores
	KUWAIT

	 	Ali Abduwa_ab, Sons & Co.
	LEBANON

	 	Mersaco S.A.
 _____ 

	LIBYA

	 	Medical Supply Organization
	OMAN

	 	Ibn Sina Pharma L.L.C.
	PAKISTAN

	 	Haroon Brothers
	QUATAR

	 	Ebn Sina Medical Est.
	SAUDI ARABIA

	 	Saphad
	U.A.E.

	 	Alphamed General Trading
	YEMEN (North)

	 	Albikma Corporation
	 
	 	 
	Africa
	 	 
	 
	 
	ANGOLA

	 	Ciba Geigy Co. Ltd.
	KENYA

	 	Kenya Swiss Chemical Co. Ltd.
	MADAGASCAR

	 	Lab. Ofafa S.A.
	MOZAMBIQUE

	 	Ciba Geigy Co. Ltd.
	NIGERIA

	 	Swiss Nigerian Chemical Co. Ltd.
	SOUTH AFRICA

	 	CIBA Vision
	SUDAN

	 	Pharma Trading Co.
	ZAIRE

	 	Societe Zairo Suisse de Produits Chimiques
	 
	 	 
	Far East
	 	 
	 
	 
	BANGLADESH

	 	Ciba Geigy Ltd.

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

82

 

	 	 	 
	COUNTRY	 	DISTRIBUTOR
	 
	 	 
	CHINA

	 	CIBA Vision
	CHINA

	 	Zuellig & Woo Co. Ltd.
	HONG KONG

	 	Zuellig Pharma Ltd.
	INDONESIA

	 	Ciba Geigy
 _____ 

	JAPAN

	 	CIBA Vision
	KOREA (South)

	 	Hanbul Pharma Co. Ltd., Searle Ciba Geigy
	MALAYSIA

	 	Zuellig Pharma Sdn. Bhd.
	NYAMAR, LAOS, CAMBODIA

	 	Ciba Geigy Ltd.
	PHILIPPINES

	 	Zuellig Pharma Corporation, Ciba Ceigy Ltd.
	SINGAPORE

	 	Zuellig Pharma etc. Ltd.
	SRI LANKA, MALDIVES

	 	CIBA
	TAIWAN

	 	CIBA Vision
	THAILAND

	 	CIBA Vision
	THAILAND

	 	Zuellig Pharma Ltd.
	VIETNAM

	 	Ciba Geigy
	 
	 	 
	Australia & New Zealand
	 	 
	 
	 
	AUSTRALIA

	 	CIBA Vision
	NEW ZEALAND

	 	CIBA Vision

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

83

 

Schedule 11.1.1: Novartis Basic International Registration Documentation

Part I: Summary of the Dossier

	 	IA	 	Marketing Authorization particulars (including proof of
payment, documents on manufacturers’ authorizations & samples)

	 	IB1:	 	Summary of Product Characteristics (SPC)

	 
	 	IB2:	 	Proposals for Packaging, Labelling & Package Insert

	 
	 	IB3:	 	SPCs already approved in the Member States

	 	IC	 	Expert Reports on chemical, pharmaceutical and clinical documentation

Part II: Chemical, Pharmaceutical and Biological Documentation

	 	II	 	 Table of Contents

	 
	 	IIA	 	Composition

	 
	 	IIB	 	Method of Preparation

	 
	 	IIC	 	Control of Starting Materials

	 
	 	IID	 	Control Tests on Intermediate Products

	 
	 	IIE	 	Control Tests on the Finished Medicinal Product

	 
	 	IIF	 	Stability

	 
	 	IIG	 	Bioavailability/bioequivalence

	 
	 	IIQ	 	ther Information

Part III: Pharmaco-Toxicological Documentation

	 	III	 	Table of Contents

	 
	 	IIIA	 	Single dose toxicity/Repeated dose toxicity

	 
	 	IIIB	 	Reproductive function

	 
	 	IIIC	 	Embryo-foetal and perinatal toxicity

	 
	 	IIID	 	Mutagenic potential

	 
	 	IIIE	 	Carcinogenic potential

	 
	 	IIIF	 	Pharmacodynamics

	 
	 	IIIG	 	Pharmacokinetics

	 
	 	IIIH	 	Local tolerance (toxicity)

	 
	 	IIIQ	 	Other Information

Part IV: Clinical Documentation

	 	IV	 	Table of Contents

	 
	 	IVA	 	Clinical Pharmacology

	 
	 	IVB	 	Clinical experience

	 
	 	IVQ	 	Other Information

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

84

 

Schedule 29.11: Novartis Affiliates

Novartis Companies 

Europe

BENELUX

DENMARK

FRANCE

GERMANY

ITALY

NETHERLANDS

NORWAY

PORTUGAL

SWEDEN

SWITZERLAND

SPAIN

TURKEY

UNITED KINGDOM

N. America

USA

CANADA

Australia and New Zealand

Australia

New Zealand

Far East

CHINA

JAPAN

TAIWAN

THAILAND

S. America

ARGENTINA

Africa

SOUTH AFRICA

	 	 	 
	[*]	 	Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions.

 

85exv10w2

Exhibit 10.2

Option No.: _______

DUOYUAN PRINTING, INC.

2009 OMNIBUS INCENTIVE PLAN

INCENTIVE STOCK OPTION AGREEMENT

Duoyuan Printing, Inc., a Wyoming corporation (the “Company”), hereby grants an option to
purchase its shares of common stock, $0.001 par value, (the “Stock”) to the optionee named
below. The terms and conditions of the option are set forth in this cover sheet, in the
attachment, and in the Company’s 2009 Omnibus Incentive Plan (the “Plan”).

Grant Date:                , 200     

Name of Optionee:                                                                   
                                                                                                                  

Optionee’s Employee Identification Number:      -     -     

Number of Shares Covered by Option:                     

Option Price per Share: $                    .      (At least 100% of Fair Market Value)

Vesting Start Date:                                         ,      

     By signing this cover sheet, you agree to all of the terms and conditions described in the
attached Agreement and in the Plan, a copy of which is also attached. You acknowledge that you
have carefully reviewed the Plan, and agree that the Plan will control in the event any provision
of this Agreement should appear to be inconsistent.

	 	 	 	 	 	 	 
	Optionee:
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Signature)
	 	 
	 
	 	 	 	 	 	 
	Company:
	 	 	 	 	 	 
	 	 	 	 	 
	 	 	(Signature)
	 	 
	 
	 	 	 	 	 	 
	 

	 	Title:	 	 	 	 
	 

	 	 	 	 
	 	 

Attachment

This is not a stock certificate or a negotiable instrument.

 

 

DUOYUAN PRINTING, INC.

2009 OMNIBUS INCENTIVE PLAN

INCENTIVE STOCK OPTION AGREEMENT

	 	 	 
	Incentive Stock Option

	 	This option is intended to be an
incentive stock option under
Section 422 of the Internal Revenue
Code and will be interpreted
accordingly. If you cease to be an
employee of the Company, its parent
or a Subsidiary (“Employee”) but
continue to provide Service, this
option will be deemed a
nonstatutory stock option three
months after you cease to be an
Employee. In addition, to the
extent that all or part of this
option exceeds the $100,000 rule of
section 422(d) of the Internal
Revenue Code, this option or the
lesser excess part will be deemed
to be a nonstatutory stock option.
	 
	 	 
	Vesting

	 	This option is only exercisable
before it expires and then only
with respect to the vested portion
of the option. Subject to the
preceding sentence, you may
exercise this option, in whole or
in part, to purchase a whole number
of vested shares not less than 100
shares, unless the number of shares
purchased is the total number
available for purchase under the
option, by following the procedures
set forth in the Plan and below in
this Agreement.
	 
	 	 
	 

	 	[Your right to purchase shares of
Stock under this option vests as to
one-fourth (1/4) of the total
number of shares covered by this
option, as shown on the cover
sheet, on the one-year anniversary
of the Vesting Start Date
(“Anniversary Date”), provided you
then continue in Service.
Thereafter, for each such vesting
date that you remain in Service,
the number of shares of Stock which
you may purchase under this option
shall vest at the rate of one-forty
eighth (1/48) per month as of the
first day of each month following
the month of the Anniversary Date.]
The resulting aggregate number of
vested shares will be rounded to
the nearest whole number, and you
cannot vest in more than the number
of shares covered by this option.
	 
	 	 
	 

	 	No additional shares of Stock will
vest after your Service has
terminated for any reason.
	 
	 	 
	Term

	 	Your option will expire in any
event at the close of business at
Company headquarters on the day
before the 10th anniversary of the
Grant Date, as shown on the cover
sheet. Your option will expire
earlier if your Service terminates,
as described below.
	 
	 	 
	Regular Termination

	 	If your Service terminates for any
reason, other than death,
Disability or Cause, then your
option will expire at the close of

2

 

	 	 	 
	 

	 	business at Company headquarters on
the 90th day after your termination
date.
	 
	 	 
	Termination for
Cause

	 	If your Service is terminated for
Cause, then you shall immediately
forfeit all rights to your option
and the option shall immediately
expire.
	 
	 	 
	Death

	 	If your Service terminates because
of your death, then your option
will expire at the close of
business at Company headquarters on
the date twelve (12) months after
the date of death. During that
twelve month period, your estate or
heirs may exercise the vested
portion of your option.
	 
	 	 
	 

	 	In addition, if you die during the
90-day period described in
connection with a regular
termination (i.e., a termination of
your Service not on account of your
death, Disability or Cause), and a
vested portion of your option has
not yet been exercised, then your
option will instead expire on the
date twelve (12) months after your
termination date. In such a case,
during the period following your
death up to the date twelve (12)
months after your termination date,
your estate or heirs may exercise
the vested portion of your option.
	 
	 	 
	Disability

	 	If your Service terminates because
of your Disability, then your
option will expire at the close of
business at Company headquarters on
the date twelve (12) months after
your termination date.
	 
	 	 
	Leaves of Absence

	 	For purposes of this option, your
Service does not terminate when you
go on a bona fide employee leave of
absence that was approved by the
Company in writing, if the terms of
the leave provide for continued
Service crediting, or when
continued Service crediting is
required by applicable law.
However, your Service will be
treated as terminating 90 days
after you went on employee leave,
unless your right to return to
active work is guaranteed by law or
by a contract. Your Service
terminates in any event when the
approved leave ends unless you
immediately return to active
employee work.
	 
	 	 
	 

	 	The Company determines, in its sole
discretion, which leaves count for
this purpose, and when your Service
terminates for all purposes under
the Plan.
	 
	 	 
	Notice of Exercise

	 	When you wish to exercise this
option, you must notify the Company
by filing the proper “Notice of
Exercise” form at the address given
on the form. Your notice must
specify how many shares you wish to
purchase (in a parcel of at least
100 shares generally). Your notice
must also specify how your shares
of Stock should be registered (in
your name only or in your and your
spouse’s names as joint tenants
with right of survivorship). The
notice will be effective when it is
received by the Company.

3

 

	 	 	 
	 

	 	If someone else wants to exercise
this option after your death, that
person must prove to the Company’s
satisfaction that he or she is
entitled to do so.
	 
	 	 
	Form of Payment

	 	When you submit your notice of
exercise, you must include payment
of the option price for the shares
you are purchasing. Payment may be
made in one (or a combination) of
the following forms:

	•	 	Cash, your personal check,
a cashier’s check, a money order or
another cash equivalent acceptable
to the Company.
	 
	•	 	Shares of Stock which have
already been owned by you and
which are surrendered to the
Company. The value of the shares,
determined as of the effective date
of the option exercise, will be
applied to the option price.
	 
	•	 	By delivery (on a form
prescribed by the Company) of an
irrevocable direction to a licensed
securities broker acceptable to the
Company to sell Stock and to
deliver all or part of the sale
proceeds to the Company in payment
of the aggregate option price and
any withholding taxes.

	 	 	 
	Withholding Taxes

	 	You will not be allowed to exercise
this option unless you make
acceptable arrangements to pay any
withholding or other taxes that may
be due as a result of the option
exercise or sale of Stock acquired
under this option. In the event
that the Company determines that
any tax or withholding payment is
required relating to the exercise
or sale of shares arising from this
grant under Applicable Laws, the
Company shall have the right to
require such payments from you, or
withhold such amounts from other
payments due to you from the
Company or any Affiliate.
	 
	 	 
	Corporate Transaction

	 	Notwithstanding the vesting
schedule set forth above, upon the
consummation of a Corporate
Transaction, this option will
become 100% vested (i) if it is not
assumed, or equivalent options are
not substituted for the options, by
the Company or its successor, or
(ii) if assumed or substituted for,
upon your Involuntary Termination
within the 12-month period
following the consummation of the
Corporate Transaction.
Notwithstanding any other provision
in this Agreement, if assumed or
substituted for, the option will
expire one year after the date of
termination.
	 
	 	 
	 

	 	“Involuntary Termination” means
termination of your Service by
reason of (i) your involuntary
dismissal by the Company or its

4

 

	 	 	 
	 

	 	successor for reasons other than
Cause; or (ii) your voluntary
resignation for Good Reason as
defined in any applicable
employment or severance agreement,
plan, or arrangement between you
and the Company, or if none, then
as set forth in the Plan following
(x) a substantial adverse
alteration in your title or
responsibilities from those in
effect immediately prior to the
Corporate Transaction; (y) a
reduction in your annual base
salary as of immediately prior to
the Corporate Transaction (or as
the same may be increased from time
to time) or a material reduction in
your annual target bonus
opportunity as of immediately prior
to the Corporate Transaction; or
(z) the relocation of your
principal place of employment to a
location more than 35 miles from
your principal place of employment
as of the Corporate Transaction or
the Company’s requiring you to be
based anywhere other than such
principal place of employment (or
permitted relocation thereof)
except for required travel on the
Company’s business to an extent
substantially consistent with your
business travel obligations as of
immediately prior to the Corporate
Transaction. To qualify as an
“Involuntary Termination” you must
provide notice to the Company of
any of the foregoing occurrences
within 90 days of the initial
occurrence and the Company shall
have 30 days to remedy such
occurrence.
	 
	 	 
	Transfer of Option

	 	During your lifetime, only you (or,
in the event of your legal
incapacity or incompetency, your
guardian or legal representative)
may exercise the option. You
cannot transfer or assign this
option. For instance, you may not
sell this option or use it as
security for a loan. If you
attempt to do any of these things,
this option will immediately become
invalid. You may, however, dispose
of this option in your will or it
may be transferred upon your death
by the laws of descent and
distribution.
	 
	 	 
	 

	 	Regardless of any marital property
settlement agreement, the Company
is not obligated to honor a notice
of exercise from your spouse, nor
is the Company obligated to
recognize your spouse’s interest in
your option in any other way.
	 
	 	 
	Retention Rights

	 	Neither your option nor this
Agreement give you the right to be
retained by the Company (or any
parent, Subsidiaries or Affiliates)
in any capacity. The Company (and
any parent, Subsidiaries or
Affiliates) reserve the right to
terminate your Service at any time
and for any reason.
	 
	 	 
	Shareholder Rights

	 	You, or your estate or heirs, have
no rights as a shareholder of the
Company until a certificate for
your option’s shares has been
issued (or an appropriate book
entry has been made). No
adjustments are made for dividends
or other rights if the applicable
record date

5

 

	 	 	 
	 

	 	occurs before your
stock certificate is issued (or an
appropriate book entry has been
made), except as described in the
Plan.
	 
	 	 
	Forfeiture of Rights

	 	If you should take actions in
competition with the Company, the
Company shall have the right to
cause a forfeiture of your rights,
including, but not limited to, the
right to cause: (i) a forfeiture of
any outstanding option, and (ii)
with respect to the period
commencing twelve (12) months prior
to your termination of Service with
the Company and ending twelve (12)
months following such termination
of Service (A) a forfeiture of any
gain recognized by you upon the
exercise of an option or (B) a
forfeiture of any Stock acquired by
you upon the exercise of an option
(but the Company will pay you the
option price without interest).
Unless otherwise specified in an
employment or other agreement
between the Company and you, you
take actions in competition with
the Company if you directly or
indirectly, own, manage, operate,
join or control, or participate in
the ownership, management,
operation or control of, or are a
proprietor, director, officer,
stockholder, member, partner or an
employee or agent of, or a
consultant to any business, firm,
corporation, partnership or other
entity which competes with any
business in which the Company or
any of its Affiliates is engaged
during your employment or other
relationship with the Company or
its Affiliates or at the time of
your termination of Service. Under
the prior sentence, ownership of
less than 1% of the securities of a
public company shall not be treated
as an action in competition with
the Company.
	 
	 	 
	 

	 	If it is ever determined by the
Board that your actions have
constituted wrongdoing that
contributed to any material
misstatement or omission from any
report or statement filed by the
Company with the U.S. Securities
and Exchange Commission, gross
misconduct, breach of fiduciary
duty to the Company, or fraud,
then the option shall be
immediately forfeited and
cancelled; provided, however, that
if the option has been exercised
within two years prior to the Board
of Directors determination, you
shall be required to pay to the
Company an amount equal to the
difference between the aggregate
value of the shares acquired upon
such exercise of the option at the
date of the Board determination and
the aggregate exercise price you
paid. In addition, the option and
gains resulting from the exercise
of the option, shall be subject to
forfeiture in accordance with the
Company’s standard policies
relating to such forfeitures and
clawbacks, as such policies are in
effect at the time of grant of the
Option.
	 
	 	 
	Adjustments

	 	In the event of a stock split, a
stock dividend or a similar change
in the Stock, the number of shares
covered by this option and the

6

 

	 	 	 
	 

	 	option price per share shall be
adjusted (and rounded down to the
nearest whole number) if required
pursuant to the Plan. Your option
shall be subject to the terms of
the agreement of merger,
liquidation or reorganization in
the event the Company is subject to
such corporate activity.
	 
	 	 
	Applicable Law

	 	This Agreement will be interpreted
and enforced under the laws of the
state of Wyoming, other than any
conflicts or choice of law rule or
principle that might otherwise
refer construction or
interpretation of this Agreement to
the substantive law of another
jurisdiction.
	 
	 	 
	The Plan

	 	The text of the Plan is
incorporated in this Agreement by
reference. Certain capitalized
terms used in this Agreement are
defined in the Plan, and have the
meaning set forth in the Plan.
	 
	 	 
	 

	 	This Agreement and the Plan
constitute the entire understanding
between you and the Company
regarding this option. Any prior
agreements, commitments or
negotiations concerning this option
are superseded.
	 
	 	 
	Data Privacy

	 	In order to administer the Plan,
the Company may process personal
data about you. Such data includes
but is not limited to the
information provided in this
Agreement and any changes thereto,
other appropriate personal and
financial data about you such as
home address and business addresses
and other contact information,
payroll information and any other
information that might be deemed
appropriate by the Company to
facilitate the administration of
the Plan.
	 
	 	 
	 

	 	By accepting this option, you give
explicit consent to the Company to
process any such personal data.
You also give explicit consent to
the Company to transfer any such
personal data outside the country
in which you work or are employed,
including, with respect to non-U.S.
resident Optionees, to the United
States, to transferees who shall
include the Company and other
persons who are designated by the
Company to administer the Plan.
	 
	 	 
	Consent to Electronic Delivery

	 	The Company may choose to deliver
certain statutory materials
relating to the Plan in electronic
form. By accepting this option
grant you agree that the Company
may deliver the Plan prospectus and
the Company’s annual report to you
in an electronic format. If at any
time you would prefer to receive
paper copies of these documents, as
you are entitled to, the Company
would be pleased to provide copies.
Please contact [          ] at
[          ] to request paper
copies of these documents.

7

 

	 	 	 
	Certain Dispositions

	 	If you sell or otherwise dispose of
Stock acquired pursuant to the
exercise of this option sooner than
the one year anniversary of the
date you acquired the Stock, then
you agree to notify the Company in
writing of the date of sale or
disposition, the number of share of
Stock sold or disposed of and the
sale price per share within 30 days
of such sale or disposition.
	 
	 	 
	Electronic Signature

	 	All references to signatures and
delivery of documents in this
Agreement can be satisfied by
procedures the Company has
established or may establish for an
electronic signature system for
delivery and acceptance of any such
documents, including this
Agreement. Your electronic
signature is the same as, and shall
have the same force and effect as,
your manual signature. Any such
procedures and delivery may be
effected by a third party engaged
by the Company to provide
administrative services related to
the Plan.

     By signing the cover sheet of this Agreement, you agree to all of the terms and
conditions described above and in the Plan.

8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00164-of-00352.parquet"}]]